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ABSTRACT 
INTRODUCTION: Growing evidence supports the use of therapeutic drug monitoring 
(TDM) to guide anti-tumour necrosis factor (TNF) drug treatment among patients with 
inflammatory bowel disease (IBD). Currently, TDM for anti-TNF drugs is variably 
practiced by gastroenterologists in Australia. Our aim was to develop consensus 
statements for TDM of anti-TNF drugs in IBD that will be endorsed by the Australian 
IBD Association (AIBDA) of the Gastroenterological Society of Australia (GESA). 
METHODS: A consensus committee of 25 Australian and international experts was 
assembled. A systematic literature search aided the steering committee in developing 
the initial draft statements. A modified Delphi technique was used with three iterations, 
with modification of statements based on feedback and anonymous voting. 
Statements with 80% agreement without reservation or only minor reservation in the 
third voting round were accepted as consensus. 
RESULTS: 22/24 statements met criteria for consensus. The committee agreed that 
TDM for anti-TNF agents should be performed upon treatment failure, following 
successful induction, when contemplating a drug-holiday and periodically in clinical 
remission only when results would change management. To achieve clinical remission 
in luminal IBD, infliximab and adalimumab trough concentrations in the range of 3-8 
µg/mL and 5-12 µg/mL, respectively, were determined as appropriate. The therapeutic 
range may need to be altered for different disease phenotypes or treatment endpoints. 
In treatment failure, TDM may identify mechanisms to guide subsequent decision-
making. Among patients in remission, TDM-guided anti-TNF drug dose optimisation 
may reduce treatment cost and avoid future relapse. Data indicates drug-tolerant anti-
drug antibody assays do not offer an advantage over drug-sensitive assays in 
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predicting outcomes. Further data are required prior to recommending TDM for non-
anti-TNF biologics. 
CONCLUSION: These consensus statements are expected to aid use of TDM by 
gastroenterologists in Australia and abroad to guide anti-TNF drug treatment in IBD 
patients. 
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1. INTRODUCTION 
1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD), a chronic inflammatory condition of the 
gastrointestinal tract (GIT), includes Crohn's disease (CD) and ulcerative colitis (UC). 
Symptoms of IBD vary and may include abdominal pain, diarrhoea and per rectal 
bleeding. UC affects the mucosal layer of the bowel in continuity from the anus and 
extending to varying lengths of the colon. In contrast, CD affects the full thickness of 
the bowel wall, can occur in any part of the GIT from mouth to anus, and lesions are 
not necessarily continuous. IBD is also a systemic disorder and can affect the eyes, 
bones, joints, skin, haematological system, urogenital tract, respiratory tract and 
cardiovascular system.[1] The widely accepted hypothesis is that IBD is an aberrant 
immune response to enteric commensal microbes, in a genetically predisposed host 
exposed to environmental triggers.[2]  
Incidence and prevalence of IBD varies greatly between populations around the 
world.[3] Reported incidence ranges from 0.0 to 29.3 per 100,000 for UC and 0.0 to 
19.2 per 100,000 for CD. Reported prevalence for UC ranges from 2.42 to 298.5 per 
100,000 and that for CD ranges from 0.6 to 318.5 per 100,000. Highest incidence and 
prevalence rates have been reported in North America, Europe, Australia and New 
Zealand. Most studies of CD and UC at different time points from various populations 
around the world have demonstrated a statistically significant increase in incidence 
with time (75% of CD studies, 60% of UC studies, P value (P) < 0.05).[4] A population 
based study in Olmsted County, Minnesota, USA, demonstrated a marked rise in 
incidence of both UC and CD from 1940s to the 1970s (1.0 cases per 100,000 person-
years to 7.8 cases per 100,000 person years for CD, and 0.6 cases per 100,000 
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person years to 9.4 cases per 100,000 person-years for UC).[4-6] It is postulated that 
improved hygiene, altered diet and antibiotic use within a population, which follows 
industrialisation, alters the gut microbiota and the immune system’s interaction with it, 
predisposing to IBD.[7] As a result developing countries are currently experiencing a 
rise in IBD incidence. 
IBD is not curable and treatment involves induction of remission followed by 
maintenance treatment. Induction of remission in IBD has classically relied on 
corticosteroids, 5-aminosalicylates and immunomodulators such as thiopurines and 
methotrexate.[8, 9] More recently developed biologic drugs are large protein 
molecules, usually monoclonal antibodies, which bind and inhibit a molecular target. 
The first developed biologic, infliximab, targets tumour necrosis factor (TNF). TNF is a 
major inflammatory cytokine in IBD pathogenesis. Infliximab and other anti-TNF 
biologics, adalimumab, certolizumab and golimumab, have proven effective at 
inducing and maintaining remission in IBD.[10-13] Newly developed biologic drugs 
effective in IBD also include vedolizumab, which blocks lymphocyte trafficking by 
inhibiting integrin α4β7, and ustekinumab, an inhibitor of the pro-inflammatory 
cytokines Interleukin 12 and 23 (IL12/23). 
 
1.2 Anti-tumour necrosis factor drugs for treatment of inflammatory bowel 
disease 
Anti-TNF drugs are used in inflammatory and auto-inflammatory conditions such as 
IBD, Ankylosing spondylitis (AS) and Rheumatoid arthritis (RA). Infliximab, is a mouse-
human chimeric monoclonal IgG1 antibody that consists of a human common (Fc) 
domain and a mouse variable (Fv) domain responsible for TNF binding. Early on, 
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development of antibodies to infliximab (ATI) was recognised as an important 
mechanism for treatment failure and infusion reactions.[14] Newly developed anti-TNF 
agents have aimed to reduce immunogenicity, loss of response and side effects.[15]   
The humanised monoclonal antibodies adalimumab and golimumab, have a human 
Fc and Fv domain. Of these only adalimumab is currently available in Australia. 
Adalimumab has not been compared to infliximab in head-to-head randomised 
studies. Although network meta-analysis and non-randomised studies indicate similar 
efficacy at inducing and maintaining remission, adalimumab may be superior to 
infliximab in maintaining remission in CD, while infliximab may be superior to 
adalimumab at inducing remission in UC.[16-18] Although development of anti-drug 
antibodies is less with adalimumab than infliximab, rates of adverse reactions and 
secondary loss of response appear to be similar between these two anti-TNF 
agents.[16-21]  
Anti-TNF drugs that lack complete monoclonal antibody structure have proven less 
efficacious in IBD. Certolizumab, a pegylated monoclonal human F[ab’]2 fragment that 
lacks an Fc antibody portion, was intended to reduce side-effects related to anti-TNF 
agents interacting with Fc receptors of immune cells. An initial randomised controlled 
trial (RCT) demonstrated no difference in the primary endpoint of clinical remission 
between the certolizumab and placebo groups, however there was increased rates of 
response in the certolizumab group at week 6.[22] The TNF receptor II-Fc fusion 
peptide entanercept was intended to increase specificity for TNF binding, following 
findings that anti-TNF monoclonal antibodies also bind other targets.[15] It was hoped 
this would reduce infusion reactions. However, although effective in rheumatoid 
arthritis and ankolysing spondylitis, entanercept has failed to demonstrate benefits in 
IBD.[23-25]   
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TNF is synthesised as a transmembrane protein by macrophages and other immune 
cells.[26] Membrane-bound TNF is subsequently cleaved to release soluble TNF. 
Membrane-bound and soluble TNF differ in their ability to activate one of two TNF 
receptors. TNF receptor 1 is activated by both soluble and membrane-bound TNF, 
and promotes transcription of genes responsible for inflammation and apoptosis. TNF 
receptor 2 is predominantly activated by membrane-bound TNF, and stimulates cell 
survival and healing. Anti-TNF agents differ in their ability to bind membrane-bound, 
soluble TNF, and soluble TNF bound to its cell surface receptor. Anti-TNF agents 
impart their anti-inflammatory action via a number of mechanisms including clearance 
of soluble TNF and passive induction of T cell apoptosis through deprivation of TNF-
dependant survival signalling, or active induction of apoptosis via antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC 
and CDC are crucially dependent on presence of an Fc region on the anti-TNF drug 
molecule, and are most efficiently performed by the monoclonal antibodies infliximab, 
adalimumab and golimumab.[15] These mechanisms may be vital for the efficacy of 
anti-TNF agents in IBD and would explain the reduced effectiveness of certolizumab 
and lack of efficacy of entanercept in IBD. 
Unfortunately, not all patients gain adequate disease control with anti-TNF therapy. 
Primary non-response is failure to respond to induction therapy, while secondary loss 
of response is disease flare following an initially demonstrated response to 
therapy.[27] Following initial induction therapy, primary non-response affects 10-30% 
of patients, while clinical remission, a harder endpoint to treatment, was only achieved 
in 45.3% and 24.2% of patients in infliximab and adalimumab studies respectively.[12, 
13, 28] For those that respond to induction treatment, secondary loss of response 
affects 23-46% of anti-TNF treated IBD patients at 12 months.[27] There is potential 
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for significant health gains if we can optimise anti-TNF drug therapy. Recently TDM 
has emerged as a promising means of optimising treatment with anti-TNF drugs in 
IBD. TDM of anti-TNF drugs involves measurement of drug levels and anti-drug 
antibodies to help guide decisions around dose adjustment and timing of switching to 
alternate therapy. TDM of anti-TNF drugs is one aspect of personalised IBD therapy 
which is currently practiced.  
 
1.3 Treatment of inflammatory bowel disease with anti-TNF drugs in the 
Australian context 
Healthcare in Australia is predominantly public, with medications funded by the 
Pharmaceutical Benefits Scheme (PBS). The PBS has approved two anti-TNF agents, 
infliximab and adalimumab, and the lymphocyte trafficking inhibitor, vedolizumab, for 
treatment of both CD and UC.[29, 30] Ustekinumab has also recently been approved 
for CD treatment only. To qualify for treatment with biologics, a patient with either UC 
or CD must meet criteria for initiation of biologic therapy (Table 1). Similarly, an 
adequate response as defined by PBS criteria must be demonstrated on subsequent 
assessments in order to qualify for ongoing treatment with biologics. Patients who fail 
one biologic can transition onto another under the PBS, and currently UC and CD 
patients are permitted a maximum of three and four treatment failure events 
respectively, before they no longer qualify for PBS subsidised biologic therapy. 
The PBS currently funds a fixed induction and maintenance regimen for both infliximab 
and adalimumab. Infliximab induction dosing involves administering 5mg/kg 
intravenously (IV) at weeks 0, 2 and 6, followed by 5mg/kg every 8 weeks. The 
standard dosing regimen for adalimumab involves subcutaneous (SC) administration 
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of 160mg at week 0, 80mg at week 2, then 40mg every 2 weeks as maintenance. 
Currently the PBS does not support a trial of dose escalation for patients with primary 
non-response or secondary loss of response to either infliximab or adalimumab, 
however pharmaceutical companies have been providing additional doses of these 
anti-TNF drugs under compassionate access schemes. As such many 
gastroenterologists in Australia practice dose escalation for patients failing treatment. 
Pharmaceutical companies have not advised how long they will continue to supply 
compassionate doses of anti-TNF drug and the PBS has not announced any plans to 
fund dose intensification in the future.  
The approach to patient's failing anti-TNF therapy varies widely among 
gastroenterologists in Australia. On documented anti-TNF drug failure, the range of 
current practices includes: 1) empirically switching to another biologic drug, either 
within or out-of-class; 2) empirically trialling anti-TNF dose escalation and if this fails 
switching to another biologic drug; or 3) a TDM-guided approach. A TDM-guided 
approach during anti-TNF treatment failure may elicit mechanisms of failure to better 
select patients likely to respond to dose escalation, switching within class or switching 
out-of-class. As such patients are likely to be commenced on effective treatment 
sooner than with empiric treatment changes. In addition, TDM-guided anti-TNF drug 
dose optimisation for stable patients maintained in remission may reduce treatment 
cost and future risk of disease relapse. TDM-guided anti-TNF drug treatment is a 
useful means of individualising IBD treatment that is currently underutilised by 
gastroenterologists in Australia and abroad. Anecdotally, barriers for 
gastroenterologists using a TDM-guided approach to anti-TNF therapy in Australia 
includes lack of awareness of the available tests, when to perform TDM and how to 
interpret and act on results. North American and European practice guidelines are not 
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entirely applicable to the Australian context due to differences in the available assays 
and the funding structure for medications in Australian.[31] The aim of this project was 
to establish a committee of local and international experts in IBD and TDM, in order to 
develop a set of consensus statements on TDM-guided anti-TNF therapy in IBD that 
will be endorsed by the Australian Inflammatory Bowel Disease Association (AIBDA) 
of the Gastroenterological Society of Australia (GESA). It is hoped that the resultant 
consensus statements will help Australian gastroenterologists utilise TDM of anti-TNF 
drugs to improve the care of IBD patients. 
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Table 1: Criteria for initial and continuing treatment with biologics for adult Crohn’s 
Disease and Ulcerative colitis on the PBS[29, 30, 32] 
Disease & 
phenotype 
Criteria for initiation Criteria for adequate 
response to qualify for 
continuation (reassessed at 
24 week intervals following 
induction) 
Moderate to 
severe UC 
A) Failure to achieve adequate 
response to or intolerance of 5-
aminosalicylates (adequate 
induction doses), and at least 
one of the following 
medications: 
1. Azathioprine (≥2mg/kg daily 
for ≥3 months) 
2. 6-Mercaptopurine (≥1mg/kg 
daily for ≥3 months) 
3. Tapered course of steroids 
(starting at least 40mg 
prednisolone and tapering 
over at least 6 weeks) 
followed by ≥3 months of 
appropriately dosed 
thiopurine agent. 
Partial Mayo score ≤2, with all 
sub-scores ≤1  
9 
 
 
B) AND at least one of: 
1. Mayo score ≥6 
2. Partial Mayo score ≥6 with 
rectal bleeding and stool 
frequency sub-scores both 
≥2 
Luminal 
Crohn’s 
disease 
A) Failure to achieve adequate 
response to or intolerance of 
tapered course of steroids 
(starting at least 40mg 
prednisolone and tapering over 
at least 6 weeks), and at least 
one of the following 
medications: 
1. Azathioprine (≥2mg/kg daily 
for ≥3 months) 
2. 6-Mercaptopurine (≥1mg/kg 
daily for ≥3 months) 
3. Methotrexate (≥15mg for ≥3 
months) 
 
B) AND 
CDAI ≤150, OR 
 
At least one of: 
1. Normalisation of platelet 
count  
2. ESR ≤25mm/hr  
3. CRP ≤15mg/L  
4. Normalisation of lactoferrin  
5. Normalisation of calprotectin  
6. Imaging evidence of 
mucosal healing 
7. Reversal of high faecal 
output state 
8. Assessed as no longer 
requiring surgery or TPN 
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CDAI ≥300, OR 
At least one of: 
1. Radiological evidence of 
>50cm of small intestinal 
involvement and CDAI ≥220  
2. Short gut syndrome or 
ileostomy or colostomy  
AND at least one of: 
1. Elevated platelet count  
2. ESR>25mm/hr 
3. CRP>15mg/L 
4. Elevated faecal lactoferrin  
5. Elevated faecal calprotectin 
6. Imaging evidence of active  
mucosal inflammation 
7. Assessed as being in a high 
faecal output state 
8. Assessed as requiring 
surgery or TPN as the next 
therapeutic option in 
absence of biologic disease 
modifying drugs. 
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Fistulising 
Crohn’s 
disease 
Complex refractory fistulising 
CD with externally draining 
enterocutaneous or 
rectovaginal fistula 
A Fistulae Symptom Grading 
Score less than baseline 
assessment score 
CD, Crohn's disease; CDAI, Crohn's disease activity index; CRP, C reactive peptide; ESR, 
erythrocyte sedimentation rate; TPN, total parenteral nutrition; UC, Ulcerative colitis 
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1.4 Consensus methods 
Guidelines obtained via a consensus are of greater value than individual opinions. The 
Delphi method and its variations are a popular approach to obtaining a consensus 
from a panel of experts.[33, 34] The Delphi method employs several rounds of voting 
from an expert committee. Following each round the level of agreement for various 
statements is quantified, and individual panel members receive anonymous feedback 
on how their voting compared to the rest of the consensus committee. Each round 
permits individual panel members to change their position based on the opinions of 
the rest of the consensus committee, and anonymity facilitates this by removing 
pressures of dominant individuals. With each iteration of the Delphi method it is 
expected the group will move closer towards a consensus, with diminishing benefits 
beyond three to four iterations.[33, 35-38] Traditionally the first round of the Delphi 
method involves an open-ended questionnaire to collect ideas from panel members, 
which will be used as the basis for the structured questionnaire in subsequent rounds. 
A common modification of the Delphi method is for the first round to start with a 
structured questionnaire based on a literature review.[33] A panel of appropriate 
experts in the field is crucial for the validity of the Delphi method.[33, 34]  
Within Australia, the National Health and Medical Research Council (NHMRC) has 
developed a system to aid developers of national healthcare guidelines, whereby each 
guideline recommendation is assigned a rating for level of evidence and grade of 
recommendation.[39] The level of supporting evidence is rated I - IV depending on the 
appropriateness of available studies in answering the particular clinical question 
(Appendix, Table 1). Grades of recommendation (A-D) for each statement are 
assigned based on five domains: available evidence base, consistency of the 
evidence, clinical impact of the recommendation, generalisability of the evidence to 
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the intended population and applicability of the recommendation to the Australian 
healthcare context (Appendix, Tables 2 & 3).   
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2. METHODS 
2.1 Steering committee and consensus committee 
A steering committee was initially formed (RL, JMA, SC, GM, NM). At the start, the 
steering committee decided on a timeline for work, composition of the consensus 
committee and criteria for nomination of panel members to the consensus committee. 
It was agreed for panel to consist of 15-25 gastroenterologists, 1 immunologist and 1-
3 clinical pharmacologists/pharmacists, and to invite 2-3 international experts in the 
field of TDM for anti-TNF drugs. Criteria for nomination of gastroenterologists to the 
panel were as follows: publications in the IBD field over the last 12 months AND a 
demonstrated commitment to the IBD field through work in dedicated high-volume IBD 
clinics OR affiliation with an IBD association. The nominated immunologist and clinical 
pharmacologists/ pharmacists were to have expertise in TDM of anti-TNF drugs. The 
steering committee proceeded to nominate panel members who were subsequently 
invited.  
 
2.2 Literature search 
A structured literature search was performed to aid drafting of the consensus 
statements (NM). A set of broad clinical questions were formulated to guide the search 
(Table 2). A literature search was performed in May/ June 2016 in Pubmed and 
Medline using the search terms: Inflammatory Bowel Disease OR Crohn's disease OR 
Ulcerative Colitis AND Therapeutic drug monitoring AND Infliximab OR Adalimumab 
OR anti-Tumour Necrosis Factor. The abstracts, and if necessary the whole paper, of 
identified articles were screened for relevance to the pre-determined clinical questions. 
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Original articles and literature reviews relevant to answering at least one of the pre-
determined clinical question were included. Additional papers and conference 
abstracts were obtained from the references section, searching abstracts from major 
international conferences and from consensus committee members. NM compiled the 
relevant articles and prepared a summary of the evidence. This was initially made 
available to steering committee members, and subsequently was distributed to all 
consensus members following the first round of voting. 
Table 2: Pre-determined clinical questions for literature search. Where 
appropriate questions were worded in the PICO format (Patient, Intervention, 
Comparator, Outcome).[40] 
Pre-determined clinical questions 
1. Among IBD patients treated with anti-TNF drugs (P), what are appropriate 
adalimumab and infliximab steady state trough therapeutic ranges (I, C) for 
remission (O)? 
2. Among IBD patients treated with anti-TNF drugs (P) does presence of anti-
drug antibodies (I) versus no anti-drug antibodies (C) affect response (O)? 
3. Among patients treated with anti-TNF drugs, are drug levels and anti-drug 
antibodies measured by different assays comparable? 
4. Among IBD patients failing anti-TNF drug treatment (P), does TDM-guided (I) 
versus clinically-guided (C) anti-TNF drug treatment result in improved clinical 
outcomes or reducing health-related cost (O)? 
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5. Among IBD patients in remission on anti-TNF drug treatment (P), does TDM-
guided (I) versus clinically-guided (C) anti-TNF drug treatment result in improved 
clinical outcomes or reducing health-related cost (O)? 
6. What is the ideal TDM-guided treatment decision algorithm to follow for IBD 
patients on anti-TNF drug treatment who have active disease, and for those in 
remission? 
7. In what clinical context is TDM helpful/ not helpful in guiding anti-TNF therapy? 
8. Among IBD patients treated with non-anti-TNF biologic drugs (P), does TDM-
guided (I) versus clinically-guided (C) biologic drug treatment result in improved 
clinical outcomes (O)? 
  
2.3 Production of initial draft of the consensus statements 
The first draft of the consensus statements was compiled by NM based on current 
evidence and international practice. The statements were distributed to members of 
the steering committee and discussed and refined on a meeting. The redrafted 
statements were reviewed for a second time by the steering committee as well as 
three other expert members from the consensus committee (NVC, CS, MW). The draft 
consensus statements were further refined based on feedback from the second round 
of review. The steering committee approved the final draft of the consensus 
statements prior to distribution to the rest of the consensus committee. 
 
2.4 Voting 
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A modified Delphi method was employed with three rounds of voting in order to reach 
a consensus (Figure 1). The first two voting rounds were completed online using 
SurveymonkeyTM, while the final round of voting was a face-to-face session. Each 
consensus committee member was permitted to vote only once for each statement. 
Level of agreement with each statement was rated as: 1) agree without reservation, 
2) agree with minor reservation, 3) agree with major reservation, 4) disagree with some 
reservation, 5) disagree without reservation, or 6) reserved. Consensus committee 
members could also leave an optional comment in relation to each statement. 
Between each voting round statements were modified based on voting results and 
comments from panellists. Compiled anonymous voting results were distributed to 
committee members following the two online voting rounds. The results of the literature 
search, including original papers and abstracts, as well as a summary of the evidence, 
were made available to all committee members via DropboxTM following the first voting 
round. Committee members were given an opportunity to review the papers and 
abstracts from the literature search and evidence summaries prior to the second voting 
round. Committee members had access to the literature search papers and abstracts 
and evidence summaries through to the third and final voting round.  
In the final voting round each committee member was allocated responsibility over one 
or two statements. They closely examined the evidence surrounding that statement/s 
and presented it to the consensus committee on the face-to-face session held in 
Sydney, in January 2017. Statements with lower degree of agreement in the second 
voting round were allocated more time: statements with < 80% agreement with no/ 
minor reservation were allocated 15minutes, those with ≥ 80% but < 90% agreement 
were allocated 10 minutes, statements with ≥ 90% were allocated 5 minutes. The 
sequence followed for each statement was as follows: presentation of the evidence 
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base, discussion, modification of the statement if necessary, and voting. Statements 
with 80% of votes as agree without reservation or agree with minor reservation were 
accepted as consensus. Failure for consensus allowed the statement to be revised 
and revoted once only. For each statement, consensus committee members agreed 
on the NHMRC level of evidence and NHMRC grade of recommendation (Appendix, 
Tables 1, 2 and 3). Spearman’s ranked order correlation was used in IBM SPSSTM to 
assess the relationship between NHMRC level of evidence and grade of 
recommendation.  
 
Figure 1: Flow diagram for the implemented modified Delphi method. 
 
 
  
Proposed draft consensus statements
1st round of voting 
Draft of consensus statements modified based 
on voting results and feedback
2nd round of voting 
Draft of consensus statements modified based 
on voting results and feedback
3rd round of voting
(face-to-face)
Statements with ≥80% agreement with no/ 
minor reservation accepted as consensus
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3. LITERATURE REVIEW 
3.1 Mechanisms of anti-TNF failure based on therapeutic drug monitoring  
TDM for patients with active disease while on anti-TNF therapy, either primary non-
response or secondary loss of response, may reveal mechanisms of treatment failure 
and help guide clinical decisions (Table 3).[19, 41-45] Confirmed active inflammatory 
disease despite therapeutic levels suggests pharmacodynamic failure. In this patient 
group, intestinal inflammation is driven predominantly by non-TNF pathways, or other 
inflammatory pathways can compensate for TNF inhibition, and such patients do not 
benefit significantly from being on an anti-TNF agent.  
Table 3: Mechanisms of anti-TNF drug failure based on therapeutic drug 
monitoring results[19]  
 Anti-TNF drug levels 
Sub-therapeutic Therapeutic 
Anti-drug 
antibodies 
Absent 
Non-immune mediated 
PK failure 
 
 
PD failure 
Present 
Immune-mediated PK 
failure 
Potentially PD failure with 
non-functional anti-drug 
antibodies (only relevant 
to drug-tolerant assays) 
PD, Pharmacodynamic; PK, Pharmacokinetic 
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Active disease in the context of sub-therapeutic levels suggests pharmacokinetic 
failure, that is treatment failure due to inadequate drug exposure. Pharmacokinetic 
failure can further be subdivided into immune-mediated and non-immune-mediated 
based on presence or absence of anti-drug antibodies, respectively. Anti-drug 
antibodies may bind the anti-TNF drug and either directly interfere with its function or 
increase its clearance. Patients with non-immune mediated pharmacokinetic failure 
are either under dosed or have increased clearance due to inter-individual variability. 
Such individuals need a higher than standard dose of the anti-TNF drug in question in 
order to reach therapeutic levels. Non-compliance with dosing needs to be excluded 
in such patients.  
Molecular mechanisms of failure vary between primary non-response and secondary 
loss of response. Pharmacokinetic failure in primary non-response is from increased 
drug clearance due to genetic factors, increased inflammatory load, or early anti-drug 
antibody production.[46] Anti-TNF drugs that are monoclonal antibodies are cleared 
from the circulation by phagocytic cells of the reticuloendothelial system, via Fcγ 
receptor (FcγR) dependant uptake.[46, 47] Certain polymorphisms of the FcγR 
increase clearance of both infliximab and adalimumab.[48] Other genetic 
polymorphisms likely exist to account for variation in anti-TNF drug elimination 
between individuals. Development of ATI has been documented during induction 
therapy and may contribute to primary non-response.[46, 49] In secondary loss of 
response, pharmacokinetic failure is predominantly from anti-drug antibodies and non-
genetic factors that increase drug clearance via non-immune mechanisms.  
Pharmacodynamic failure in primary non-response may be due to genetic or disease 
factors that result in non-TNF inflammatory pathways having a role, while in secondary 
loss of response it has been postulated that anti-TNF therapy can eventually promote 
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non-TNF inflammatory pathways.[46, 50] Genetic polymorphisms in TNF receptor 1, 
the FcγR as well as the apoptosis pathway proteins Fas, Fas Ligand and Caspase 9 
have been shown to reduce responsiveness to infliximab.[46, 51-54] In a subset of 
individuals anti-TNF therapy for immune mediated conditions may trigger other 
paradoxical inflammatory conditions, the most well described being psoriatic skin 
reactions.[50, 55-57] Anti-TNF therapy in mouse models of rheumatoid arthritis has 
been shown to increase peripheral levels of Th1 and Th17 cells, and may provide a 
mechanistic explanation for the above paradoxic pro-inflammatory effects.[50, 58] 
Similarly with prolonged anti-TNF drug treatment in IBD, promotion of alternate 
inflammatory pathways within the bowel may lead to secondary loss of response. 
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3.2 Endpoints of IBD treatment  
To implement TDM-guided anti-TNF therapy for IBD patients, endpoints of treatment 
need to be clearly defined. This is the so-called treat-to-target approach. Classically 
IBD trials have focused on clinical remission, as defined by clinical scoring tools such 
as the Crohn's Disease Activity Index (CDAI), Harvey Bradshaw Index (HBI) or Mayo 
Score. However, more recently endoscopic remission and histological remission have 
received attention as treatment endpoints.[59, 60] 
Patients who achieve endoscopic remission, defined as no visible lesions on 
endoscopy, have improved outcomes compared to patients only achieving clinical 
remission. In a prospective study of CD patients followed up for 4 years, endoscopic 
remission at year 2 was the only factor predictive of steroid-free remission at years 3 
and 4 (70.8% versus 27.3%, P = 0.036, odds ratio (OR) = 4.352, 95% Confidence 
interval (95%CI) 1.10-17.220).[61] In addition, the risk of colorectal cancer in UC 
patients who achieve endoscopic remission reduces back to that of the general 
population.[62] Histological remission indicates resolution of microscopic signs of 
inflammation. Currently it is a difficult treatment target to recommend owing to 
disagreement on standardised definition, issues with sampling error and lack of 
evidence of long term benefit beyond endoscopic remission.[60]  
Recently the International Organisation for the Study of Inflammatory Bowel Disease 
(IOIBD) recommended that a combination of patient reported outcomes remission and 
endoscopic remission should be the endpoint for both CD and UC treatment.[60] For 
CD with small bowel involvement, cross-sectional imaging may be used instead of 
endoscopy to assess for resolution of mucosal inflammation. The IOIBD recommends 
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that biomarkers such as C reactive peptide (CRP) and faecal calprotectin be used as 
adjunctive markers of inflammation, but not as endpoints of treatment.  
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3.3 Comparison of assays for measuring anti-TNF drug levels and anti-drug 
antibodies   
Assays used to measure anti-TNF drug levels and anti-drug antibody titres are broadly 
divided into drug-tolerant or drug-sensitive (Table 4).[63-65] Most commercial 
enzyme-linked immunoassay (ELISA) and radio-immunoassays (RIA) are drug-
sensitive. These are generally less expensive, but can only detect anti-drug antibodies 
in the absence of free drug in the blood sample. More recently developed drug-tolerant 
assays overcome this problem, and include the homogeneous mobility shift assay 
(HMSA) developed by Prometheus Laboratories and electrochemiluminescence 
immunoassay (ECLISA) developed by Labcorp.[63, 64, 66] Drug-tolerant assays 
include an acid disassociation step to remove free drug from the sample before 
detection of anti-drug antibodies.[46] In addition the above drug-sensitive assays can 
be made drug-tolerant by including a pre-treatment step in the protocol.[67] Increased 
sensitivity of drug-tolerant assays for detecting anti-drug antibodies in samples with 
free anti-TNF drug may identify patients at risk of immune-mediated pharmacokinetic 
failure at an earlier stage. 
Assays can also be divided as fluid-phase or solid-phase depending on the medium 
in which drug or anti-drug antibody detection occurs.[46] Solid-phase ELISAs are the 
most common assay used for measuring drug levels and anti-drug antibody titres. 
They rely on capture of drug or anti-drug antibody on a plate coated with either TNF, 
anti-TNF drug or an antibody. Fluid-phase assays, including the RIA, HMSA and 
ECLISA, detect drug or anti-drug antibodies in a fluid medium. Requirement for less 
wash steps among fluid-phase assays results in increased sensitivity for anti-drug 
antibodies with lower binding affinity, however they are more labour intensive and with 
the RIA handling of radioactive material is an additional concern.[46, 68] 
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Functional assay, such as a reporter gene assay, are unique in that they directly 
quantify the amount of anti-TNF activity in a serum sample.[19, 69] These assays were 
developed to help distinguish functional and non-functional anti-drug antibodies. 
Functional anti-drug antibodies bind the anti-TNF drug and either increase its 
clearance or interfere with binding of its target. Non-functional anti-drug antibodies on 
the other hand do not increase the clearance of the anti-TNF drug or interfere with its 
pharmacodynamic action. Although both functional and non-functional anti-drug 
antibodies may contribute to drug reactions, only functional anti-drug antibodies are of 
relevance to treatment failure. 
There is generally good correlation between anti-TNF drug levels measured by the 
different types of assays.[70, 71] One study comparing RIA, ELISA and functional 
reporter gene assay, found good correlation in measured infliximab levels (R = 0.97 - 
0.99μg/mL).[70] Another study compared the detection rates of infliximab using four 
different types of assays on the same set of blood samples from 66 CD patients.[71] 
Again there was very good correlation between the detection rates of the different 
assays: 76% ELISA, 88% HMSA, 82% RIA, and 74% functional cell-based reporter 
gene assay (Pearson's r = 0.91 - 0.97, P < 0.0001). However, of note there were 
systematic differences in measured levels between assays, with individual assays 
consistently measured higher/ lower levels relative to other assays. The highest 
correlation was found between the HMSA and the ELISA assay tested (Pearson r = 
0.97, P < 0.0001). The mean difference between levels measured by the ELISA and 
HMSA was 0.64μg/mL (0.15-1.12 μg/mL). Studies that have compared anti-TNF drug 
levels measured using different commercial ELISA kits have also found good 
correlation of measured levels, however again with small systematic differences.[72-
77] An analysis of four ELISA assays by Enciso et al. demonstrated no statistically 
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significant difference in the measured infliximab levels within the therapeutic range of 
1-10μg/mL (intraclass correlation coefficient 0.97, 95%CI 0.96 - 0.98).[76] Similarly an 
analysis by Lee et al. of three of the four commercial ELISAs approved in Australia for 
measurement of infliximab drug levels demonstrated good overall correlation between 
the three kits, however again systematic differences in measured levels were 
noted.[77] 
The above data indicates that we can generally compare drug level results obtained 
from different assays. A therapeutic drug cut-off that correlates with a specific 
treatment endpoint determined using one drug assay can generally be applied to other 
drug assays. This is expected as each assay is calibrated to the same easily 
accessible “standard”, a known concentration of the tested drug. Small systematic 
differences between measured levels may be overcome with better calibration against 
the “standard”.  
Detection of anti-drug antibodies between different assays is more variable than 
detection of drug levels. In the study by Steenholdt et al. detection rates of ATI 
between the four tested assays varied considerably: 9% by ELISA, 11% by functional 
reporter-gene assay, 27% by RIA and 33% by HMSA.[71] However when the results 
of each assay were applied to a treatment decision algorithm, the different assays lead 
to the same decision in the majority of cases (79-94%). This is another argument 
against choosing a more expensive HMSA or a more cumbersome functional assay 
over a drug-sensitive ELISA. A universal anti-adalimumab antibody standard has been 
proposed to allow comparison of antibody to adalimumab (ATA) titres between 
laboratories.[78] However this may prove to be difficult as assays differ in their ability 
to measure different antibody subtypes. Bridging and capture ELISA assays cannot 
detect monovalent IgG4 antibodies, and on average these contribute 36% of all anti-
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drug antibodies found in sera of infliximab treated patients.[20, 70, 79] The relative 
proportion of IgG4 antibodies from total ATI titres varies widely between individuals 
(range 8-89%) making adjustment between assays difficult.  
It is not clear if increased antibody detection rates by drug-tolerant assays will improve 
clinical outcomes. Fegan et al. demonstrated that presence of anti-drug antibodies 
among patients with therapeutic drug levels as detected with a HMSA was associated 
with significantly higher CRP levels (9.90mg/L vs 1.50mg/L, P < 0.01).[80] However, 
in the study by Steenholdt et al., 68% of anti-drug antibodies detected by HMSA did 
not have neutralizing potential as tested by the functional assay.[71] In another study 
detection of antibodies at secondary loss of response to infliximab via the HMSA did 
not predict for lack of response to dose escalation.[81] Alternatively, detection of anti-
drug antibodies via a drug-sensitive ELISA assay predicts lack of response to dose 
escalation for both adalimumab and infliximab.[82, 83] In a recent study, 29.6% of 
tested serum samples via a drug-tolerant ECLISA were found to have detectable ATI 
in presence of detectable infliximab levels.[84] In a post-hoc analysis of the Trough 
level Adapted infliXImab Treatment (TAXIT) trial, 62% of pre-optimisation blood 
samples were positive for ATI via the drug-tolerant assay as opposed to 21% via a 
drug-sensitive assay.[85] For the drug-tolerant assay, ATI titres in quartile 4 were 
associated with significantly higher infliximab doses to achieve therapeutic infliximab 
levels compared to quartiles 1 and 2 or patients with no ATI (P < 0.001 for all three 
comparisons). There was no statistically significant difference in required doses 
between patients with ATI titres in quartiles 3 and patients with undetectable ATI, or 
those with detectable ATI with titres in quartiles 1, 2 or 4. All but one of the patients 
with ATI titres in quartile 4 for the drug-tolerant assay were also detected as ATI 
positive via the drug-sensitive assay. This suggests that drug-tolerant assays may 
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over detect clinically irrelevant anti-drug antibodies in presence of detectable drug 
levels. This may not offer additional information to guide clinical decisions to justify the 
generally higher cost of drug-tolerant assays over drug-sensitive assays.  
Recently biosimilar medications have emerged on the market and this poses questions 
regarding the utility of currently available commercial assays for measuring levels of 
biosimilar anti-TNF drugs. One study used an ELISA assay with monoclonal 
antibodies raised against Remicade to compare reactivity to two Remicade biosimilar, 
Remisma and Inflectra.[86] The assay demonstrated equal reactivity to Remicade and 
the two biosimilars. Similarly, anti-drug antibodies in sera of infliximab treated patients 
showed very strong cross-reactivity between Remicade and the two biosimilars.  
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Table 4: Types of assays for measuring anti-TNF drug levels and anti-drug 
antibodies.[19] 
Type of Assay Description Advantage Disadvantage 
Enzyme-linked 
immunosorbent 
assay (ELISA) 
Solid-phase assay: 
plate is coated with 
TNF, anti-TNF drug 
or a fragment of the 
anti-TNF drug 
molecule, in order to 
bind either the anti-
TNF drug or anti-
drug antibodies in 
the sample, directly 
or indirectly. 
Detection antibody 
is linked to an 
enzyme which 
catalyses a colour 
reaction.  
Less expensive 
Can easily be 
performed by most 
laboratories 
Cannot detect anti-
drug antibodies in 
presence of free 
drug in the sample 
Cannot distinguish 
neutralising and 
non-neutralising 
anti-drug antibodies 
Lower detection limit 
than fluid-phase 
assays due to 
multiple wash steps 
Higher rates of false 
positive and false 
negative results 
Radio-
immunoassay (RIA) 
Fluid-phase assay: 
binding of target and 
detecting anti-
antibody occurs in 
fluid-phase. 
Detecting antibody 
is labelled with a γ-
Sensitive, can 
detect lower drug 
and anti-drug 
antibody levels 
Cannot detect anti-
drug antibodies in 
presence of free 
drug in the sample 
Cannot distinguish 
neutralising and 
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radiation emitting 
radioisotope. 
non-neutralising 
anti-drug antibodies 
Need for radioactive 
isotopes 
Need for specialised 
laboratory facilities 
and trained 
personnel  
Homogeneous 
mobility shift assay 
(HMSA) 
Fluid-phase assay: 
acid-disassociation 
step prior to 
detection of anti-
drug antibodies. 
Fluorescent labelled 
anti-TNF drug or 
TNF is added to 
serum sample to 
detect anti-drug 
antibodies or anti-
TNF drug 
respectively. The 
complexes formed 
are separated out 
and quantified using 
size-exclusion high-
Detect anti-drug 
antibodies in 
presence of free 
drug in the sample 
Sensitive, can 
detect lower drug 
and anti-drug 
antibody levels 
Cannot distinguish 
neutralising and 
non-neutralising 
anti-drug antibodies 
Expensive 
Need for specialised 
laboratory facilities 
and trained 
personnel 
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performance liquid 
chromatography 
Electro-
chemiluminescence 
immunoassay 
(ECLISA) 
Fluid-phase assay: 
acid-disassociation 
step prior to 
detection of anti-
drug antibodies. The 
target antigen is 
captured using a 
monoclonal antibody 
linked to a magnetic 
microparticle. This 
than becomes 
bound to a magnetic 
electrode. Detection 
relies on a second 
antibody which is 
ruthenylated, and 
emits photons on 
application of a 
voltage through the 
electrode. 
Detect anti-drug 
antibodies in 
presence of free 
drug in the sample 
Sensitive, can 
detect lower drug 
and anti-drug 
antibody levels 
Cannot distinguish 
neutralising and 
non-neutralising 
anti-drug antibodies  
Expensive 
Need for specialised 
laboratory facilities 
and trained 
personnel 
Functional assay Anti-TNF activity in a 
serum sample is 
quantified using a 
reporter gene assay. 
Distinguishes 
functional and non-
functional anti-drug 
antibodies 
Need for live cell 
culture, 
cumbersome 
Expensive 
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Cells express TNF 
receptors linked to a 
reporter gene. TNF 
and the patient’s 
serum are added to 
the cell culture to 
quantify the amount 
of interference with 
TNF binding. 
Need for specialised 
laboratory facilities 
and trained 
personnel 
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3.4 Benefits of Therapeutic Drug Monitoring guided anti-TNF therapy 
3.4.1 Therapeutic drug monitoring versus clinically guided anti-TNF drug 
treatment  
Empiric dose escalation for patients failing either infliximab or adalimumab can induce 
remission in about 39-56% and 37% of patients respectively.[41, 87-89] An empiric 
dose escalation strategy for patients failing anti-TNF therapy allows for one treatment 
to be completely exhausted before moving onto another, a prudent approach in an era 
of limited biologic options.[19] However a TDM approach can potentially better select 
patients failing an anti-TNF drug likely to respond to dose escalation versus those 
likely to respond to switching within class or switching out-of-class.[82] A TDM-guided 
approach may lead to cost saving and effective treatment being commenced sooner 
compared to clinical treatment decision. 
A Danish cohort study demonstrated that a TDM-based algorithm approach compared 
to empiric dose escalation for CD patients with secondary loss of response to 
infliximab, results in similar response rates at 12 weeks (58% algorithm group versus 
53% empiric group, P = 0.81), however with 34% lower cost per patient in the algorithm 
group (P < 0.001).[41, 87] Per protocol analysis again demonstrated similar response 
rates with an even greater cost saving of 56% in the algorithm group. Follow up at 20 
weeks and 1 year, demonstrated that the algorithm group had maintained a cost 
saving of 31% and 24% respectively at these two time points over the empiric dose 
escalation group in intention-to-treat analysis.[19, 90] Quality of life scores between 
the algorithm and empiric group were similar at 20 weeks despite a greater proportion 
of patients discontinuing infliximab therapy in the algorithm group.[91] Case studies 
and simulation studies in both IBD and Rheumatology have supported these findings 
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of significant cost saving associated with TDM guided anti-TNF treatment 
algorithms.[43, 92-95] 
TDM-guided adjustment of anti-TNF drug dosing for stable patients on maintenance 
therapy, so called proactive approach, differs from the above strategy which reserves 
TDM for treatment failure events, a so called reactive approach. Low adalimumab and 
infliximab drug levels increase risk of anti-drug antibody development and treatment 
failure, and early dose escalation in such patients may prevent this issue.[31, 41, 96-
99] In one paediatric study, a week 14 infliximab trough level was strongly predictive 
of week 54 clinical remission, with trough levels of > 3μg/mL, > 4μg/mL and > 7μg/mL 
having a positive predictive value (PPV) of 64%, 76% and 100% respectively (area 
under receiver operator characteristic (AUROC) = 0.68, P = 0.03).[96] In another study 
of 332 IBD patients on maintenance infliximab therapy, an infliximab trough level < 
3μg/ml increased future risk of ATI development four-fold.[100] The increase in risk 
was associated with cumulative time spent at an infliximab concentration below 
3μg/mL. Similarly Baert et al. found a  week 4 post induction adalimumab trough level 
< 5μg/mL to be associated with a hazard ratio (HR) of 25.12 (95%CI 5.64 to 111.91, 
P = 0.0002) for development of ATA over 1 year follow up as compared to adalimumab 
trough levels > 5μg/mL.[41, 97] In this study there was a negative correlation between 
CRP and adalimumab levels (P = 0.0001) and a positive correlation between ATA and 
CRP (P = 0.0186). This suggests that early dose optimisation for patients in remission 
with sub-therapeutic trough levels may prevent subsequent secondary loss of 
response due to immune-mediated pharmacokinetic failure. When proactive TDM is 
undertaken, dose de-escalating patients with supra-therapeutic drug levels may result 
in significant cost saving without adversely affecting clinical outcomes. This may 
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completely or partially offset the cost of dose escalating patients with sub-therapeutic 
levels, and result in optimal drug distribution within a population of IBD patients.  
A prospective observational study of 80 IBD patients stably maintained on infliximab 
for at least 2 years, found that TDM-guided infliximab dose adjustment lead to 
improved clinical outcomes compared to clinically guided dose de-escalation.[101] All 
patients had TDM performed initially and treating physicians were kept blind to these 
results throughout the study. Treating physicians determined if a patient should have 
infliximab dose reduction based on clinical review and CRP alone. Patients were 
divided into two groups, depending on whether dose adjustment decisions of their 
treating physician agreed or disagreed with the predetermined TDM-based treatment 
algorithm. There was significant improvement in clinical disease activity in patients 
whose treatment decision agreed with the pre-determined TDM-based algorithm 
compared to those whose treatment decision disagreed with the algorithm (HBI 1.62 
at inclusion vs 1.06 at week 16 among CD patients, P < 0.001; Ulcerative Colitis 
Disease Activity Index (UCDAI) 1.17 at inclusion vs 0.58 at week 8 among UC patients, 
P = 0.05). There was also a significant reduction in CRP in the former group relative 
to the later (4.53 at inclusion vs 3.10 at week 16, P = 0.02). 
Benefits of proactive TDM over clinical dosing have been mixed. The TAXIT study was 
an RCT that evaluated proactive TDM against clinically-guided dosing for CD patients 
on maintenance infliximab therapy.[102] Following an initial period of TDM-guided 
dose optimisation, patients were randomised to either ongoing proactive TDM every 
infusion cycle or dose adjustment based on clinical symptoms and CRP. The study 
failed to show an advantage of the proactive TDM arm over clinical dose adjustment 
in regard to its primary endpoint of clinical remission rate at 12 months (69% versus 
66%, P = 0.686). Quality of life and cost were also very similar between the two groups. 
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However, significantly less patients in the proactive arm experienced a flare 
necessitating rescue therapy during the 12 months follow up period (7% versus 17% 
respectively, P = 0.018).  
The initial dose optimisation phase of the TAXIT study potentially negated some of the 
benefits of proactive TDM over clinically adjusted dosing. The Tailored Treatment With 
Infliximab for Active Luminal Crohn's Disease (TAILORIX) study which followed 
removed this factor.[103] Following infliximab induction, CD patients who went on to 
infliximab maintenance treatment of 5mg/kg every 8 weeks were randomised into 
three groups: 1) dose escalation in 2.5mg/kg increments (maximal of 10mg/kg) based 
on clinical symptoms, biomarkers and TDM, 2) dose escalation to 10mg/kg (one off) 
based on same criteria as group 1, or 3) dose escalation to 10mg/kg based on clinical 
criteria alone. Again, no significant difference was demonstrated between the three 
groups in terms of the primary endpoint of sustained steroid-free clinical remission 
between weeks 22 and 54 and absence of ulceration on endoscopy at 1 year (47% for 
group 1, 38% for group 2, 40% for group 3, P = non-significant (NS)). There was also 
no statistically significant difference in endoscopic remission or financial cost at 1 year 
between the three groups.  
 
3.4.2 Proactive versus reactive therapeutic drug monitoring 
Although TDM-guided dosing has demonstrated some advantages over clinically-
guided dosing, particularly with a reactive approach, it is less clear if proactive TDM 
offers an advantage over reactive TDM. A retrospective observational study compared 
outcomes for IBD patients in remission on infliximab who had proactive TDM versus 
those who had reactive TDM.[42, 104, 105] Significantly lower probability of 
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discontinuing infliximab was found with proactive TDM compared to reactive TDM 
(10% vs 31%, P = 0.009). Within the proactive TDM group the probability of stopping 
infliximab was lower still for those with trough concentration ≥ 5μg/mL (HR = 0.03, 
95%CI 0.01 - 0.1, P < 0.0001). However, patients in the proactive TDM group were all 
managed by a single gastroenterologist while the remaining gastroenterologists in the 
clinic practiced reactive TDM. Different co-therapies and methods of disease 
assessment between the two groups may be significant confounders in this study.  
 
3.4.3 Scenarios where currently TDM-guided anti-TNF agent dosing is of 
limited benefit 
In some scenarios TDM of anti-TNF agents is currently of limited benefit, either due to 
the results not being available in a sufficient timeframe to influence decisions, or due 
to lack of evidence on how to interpret results in a particular setting. Dose adjustment 
in such situations should be based on other factors. In acute severe ulcerative colitis 
(ASUC) accelerated infliximab induction has been shown to significantly reduce short 
term colectomy rates compared to standard induction dosing (6.7% versus 40%, 
Fisher exact test, P = 0.039).[43, 106] Patients with signs of breakthrough 
inflammation, low albumin, and high CRP are more likely to benefit from accelerated 
infliximab induction. Current guidelines recommend allowing a patient with ASUC no 
more than 4-7 days to respond to a trial of infliximab salvage therapy before moving 
to an urgent colectomy.[8] TDM is currently not helpful in differentiating ASUC patients 
that benefit from accelerated infliximab induction from those who should move to a 
colectomy, due to lack of data on appropriate drug levels in this scenario, as well as a 
relatively long turn-around time for results, at least for most centres in Australia. In 
future as turnaround time for infliximab drug level testing becomes less and new data 
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becomes available, a role for TDM-guided infliximab dosing for patients presenting 
with ASUC may emerge. Of note, two rapid point-of-care assay for infliximab have 
recently been validated.[107, 108] 
Anti-TNF drug exposure in utero increases risk of infections in newborn infants, 
necessitating avoidance of live vaccines for the first 6 months of life at least.[109, 110] 
Studies indicate that infliximab and adalimumab are actively transferred to the foetus 
via the placenta from 20 weeks to delivery, similarly to endogenous IgG 
antibodies.[111-114] Consequently anti-TNF levels in the newborn infant are 1.5-3 
times that of maternal peripheral blood, and anti-TNF drug remains detectable in 
infants for up to 6 months following birth.[111-114] However, currently anti-TNF drug 
levels are not routinely measured in pregnant women as it is not clear what are 
acceptable anti-TNF levels and how to dose adjust based on these in order to 
maximise disease control and minimise anti-TNF drug exposure for the newborn 
infant.   
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3.5 Target drug levels 
Most studies of anti-TNF drug levels have examined the relationship between trough 
levels and clinical outcomes. Drug trough levels are taken just prior to administration 
of the next drug dose. Although trough levels correlate best with activity for most drugs 
there are exceptions to this, particularly antibiotics such as gentamicin.[115] It is 
unclear if trough levels are the best predictor of response to anti-TNF drugs, compared 
to peak drug levels, drug levels at other points of the dosing cycle, or total drug 
exposure as defined by area under a concentration-time graph.[45, 46] Few studies 
have related drug levels at other points of the dosing cycle to clinical outcomes.[116, 
117] Interestingly, among IBD patients on maintenance infliximab, Yamada et al. found 
no difference in pre-infusion trough levels between those with maintained response 
and those with secondary loss of response (4.7μg/mL vs 6.3μg/mL, P = NS) while 
post-infusion peak levels were significantly higher among patients with maintained 
response to infliximab (149.5μg/mL vs 126.3μg/mL, P = 0.0488).[117] This was a small 
study of 31 patients and we cannot conclude with confidence that peak drug levels are 
a better predictor of treatment response to infliximab than trough levels. Several other 
cohort and cross-sectional studies have found infliximab and adalimumab trough 
levels to predict for response to treatment.[80, 82, 83, 97, 98, 116, 118-149] 
When measuring and interpreting anti-TNF drug levels we need to consider the 
distribution of drug in the body and the elimination half-life. The compartment model 
simplifies the body as different compartments between which the drug can move 
(Figure 2). Infliximab is administered by IV infusion while adalimumab is administered 
via a SC injection. Following drug administration, infliximab blood levels peak almost 
immediately, while adalimumab blood levels peak 5 days later due to slower diffusion 
out of adipose tissue.[46] Because adalimumab is administered every 2 weeks and 
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the SC route results in slower diffusion into the circulation, less variability is observed 
between peak and trough levels than with infliximab.[150] Although we measure serum 
levels of anti-TNF drugs due to convenience, concentrations at the target tissue are 
likely to relate better to their efficacy. However, circulating anti-TNF drug may also 
contribute to reducing bowel inflammation by neutralise TNF in the systemic 
circulation. It is not clear what the relative importance of this potential mechanism of 
action is in relation to neutralisation of TNF and depletion of lymphocytes via ADCC 
and CDC in the target tissue.  
 
Figure 2: Compartment model for anti-TNF drug distribution and serum anti-TNF 
drug levels in maintenance therapy.[46] 
 
 
To ensure comparable results, drug levels are typically measured once steady state 
is established. Steady state is a situation where the rate of drug administration is equal 
to the rate of drug elimination.[151] Generally a drug that is administered at a constant 
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dosing regimen would reach steady state 4 to 5 elimination half-lives from when this 
constant dosing was commenced. The half-life of both infliximab and adalimumab is 
variable between individuals. Median elimination half-life of infliximab is quoted 
between 7.7 to 9.5 days, however three population pharmacokinetic studies have 
estimated the elimination half-life of infliximab to be between 14 and 18.5 days.[152-
157] For adalimumab, median elimination half-life based on both IV and SC dosing is 
approximately 20 days.[153, 158] Based on this data, a steady state trough for 
infliximab and adalimumab can generally be taken at least 7 and 14 weeks from 
commencing a constant dosing regimen, respectively.  
Factors that lead to inter- and intra-individual variability of anti-TNF drug elimination 
half-life need to be considered. These factors including gender, body mass index 
(BMI), co-treatment with immunosuppressants, serum albumin concentration, severity 
of inflammatory burden and anti-drug antibodies.[31, 159-161] Higher BMI and male 
gender reduce anti-TNF drug elimination half-life.[153] Anti-drug antibodies that may 
develop over time can drastically increase clearance of anti-TNF agents. Concomitant 
use of immunomodulators significantly reduce production of anti-drug antibodies, with 
ATI positivity rates at week 30 of 0.9% among patients on infliximab and azathioprine 
combination therapy compared to 14.6% among those on infliximab monotherapy 
observed in the Study of Biologic and Immunomodulator Naive Patients in Crohn's 
Disease (SONIC) trial.[162] The effect of this is reduction in clearance of infliximab as 
observed in a significant rise in median trough levels among patients on combination 
therapy versus infliximab montherapy (3.5μg/mL versus 1.6μg/mL, P < 0.001).[162] 
Concomitant immunomodulator use may also increase anti-TNF trough levels 
independent of suppression of anti-TNF antibody production, through reduction of 
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inflammatory load and hence circulating TNF, or generalised reduction of antibody 
clearance by the reticuloendothelial system.[19]  
Elimination half-life is reduced if inflammatory burden is high due to increased TNF 
levels binding and clearing anti-TNF drug, as well as increased gut losses of anti-TNF 
drug.[163] Ungar et al. demonstrated lower week 2 infliximab trough levels among 
hospitalised ASUC patients compared to outpatients with moderately severe UC (7.15 
± 5.3μg/mL vs 14.4 ±1 1.2μg/mL, P = 0.007).[164] Similarly, lower infliximab 
elimination half-lives have been observed in IBD patients with high CRP and low 
albumin.[159, 160] Through this it follows that higher anti-TNF drug doses are required 
to establish therapeutic levels and achieve response in patients with high inflammatory 
burden. In a study of Rheumatoid arthritis patients, there was no difference in 
remission rates among patients with low baseline circulating TNF levels who were 
dosed with infliximab at 3mg/kg, 6mg/kg or 10mg/kg, however there was a clear trend 
towards increased remission rates with higher infliximab doses among patients with 
high baseline TNF levels.[165, 166] For patients with low baseline TNF levels all dose 
groups achieved detectable median infliximab trough levels, while among patients with 
high baseline TNF levels only the 10mg/kg group achieved detectable median trough 
levels. Among UC patients undergoing infliximab induction, significantly higher faecal 
infliximab losses have been documented among non-responders compared to 
responders (5.01μg/mL versus 0.54μg/mL, P = 0.0047).[163] Biopsies in patients with 
active inflammation have found the anti-TNF:TNF ratio to be lowest in samples with 
severe inflammation.[167] Similarly an observational study of patients undergoing 
infliximab induction for moderate-severe UC found significantly lower total infliximab 
exposure among patients whose baseline CRP was > 50mg/L compared to those with 
baseline CRP ≤ 50mg/L (587mg/L/day versus 1361mg/L/day respectively, P = 
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0.001).[168] This suggests that for response in high inflammatory states higher anti-
TNF drug doses are needed to achieve comparable drug levels, and this requirement 
for increased dose may not necessarily reflect a need for higher drug trough levels. It 
also follows that once inflammatory burden reduces (i.e. when a patient is in remission) 
lower maintenance doses may be sufficient to achieve the same therapeutic trough 
levels. 
For a given drug if a loading dose of twice the maintenance dose is administered and 
a constant dosing interval is maintained, than steady state is immediately 
achieved.[169] If the administered loading dose is greater or less than this amount 
than again 4 - 5 drug elimination half-lives need to pass for steady state to be 
established. However, these conditions are not met with standard infliximab and 
adalimumab induction regimens. There is also the added complexity of anti-TNF 
elimination half-life not being constant throughout induction and maintenance 
treatment. During induction therapy when inflammatory load is higher, elimination half-
life of anti-TNF drugs is likely to be lower due to more rapid clearance.[163]  With 
standard induction regimens, a steady state trough level can be taken as the first 
trough level 4 - 5 elimination half-lives from commencing a constant maintenance 
dosing regimen i.e. usually just before the week 14 dose from commencing infliximab 
or just before the week 18 dose from commencing adalimumab. Adalimumab displays 
smaller fluctuations in drug levels during the dosing cycle, and so timing of trough 
levels may be less critical.[150, 170] Ward et al. found that although differences in 
peak and trough adalimumab levels are relatively small they are still statistically 
significant (mean peak level 5.18µg/mL, mean trough level 4.15µg/mL, paired data, P 
< 0.001).[150] 
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Given the length of time before a steady state trough level can be taken following 
commencement of an anti-TNF drug (approximately 14 weeks for infliximab and 18 
weeks for adalimumab), relying on a steady state therapeutic trough range may not 
always be practical. Patient’s with primary non-response and severe symptoms likely 
cannot wait for a steady state trough level to be taken to guide therapeutic decisions. 
There are relatively few studies that have examined the relationship between non-
steady state trough levels during anti-TNF drug induction and response.[116, 118, 
143, 148, 171, 172] Golovics et al. demonstrated that week 2 infliximab trough levels 
among IBD patients predicted for week 14 response and remission status (for 
response AUROC = 0.715, P = 0.05; for remission AUROC = 0.721, P = 0.005).[171] 
Mean non-steady state trough levels at weeks 2 and 6 of induction were higher than 
presumed steady state trough levels at week 14 (weeks 2, 6 and 14 mean infliximab 
trough levels were 20.1μg/mL, 14.7μg/mL and 5.1μg/mL respectively). Papamichael 
et al. showed that mucosal healing among UC patients is optimally predicted by an 
infliximab concentration ≥ 28.3μg/mL at week 2 (AUROC = 0.638, P = 0.018), 
≥15μg/mL at week 6 (AUROC = 0.688, P = 0.001) and ≥ 2.1μg/mL at week 14 (AUROC 
= 0.781, P < 0.001).[116] In contrast, Adedokun et al. found week 2 induction infliximab 
trough levels not to predict for clinical response at week 8.[118] During adalimumab 
induction among paediatric CD patients, higher trough levels correlate with remission 
as compared to levels during steady state (i.e. beyond 18 weeks), with a cut-off trough 
of > 11.6μg/mL, > 5.3μg/mL and > 3.6μg/mL being optimal for predicting clinical 
remission at weeks 4, 26 and 52.[143] However in this study only the week 26 trough 
cut-off reached statistical significance. In a study among adult CD patients, a week 4 
adalimumab level of ≥ 16.2μg/mL was found to be optimal for predicting clinical 
response at week 24 (92% sensitivity, 67% specificity, AUROC = 0.81).[172] 
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In order to apply TDM-guided therapy for anti-TNF drugs, in active disease a 
therapeutic cut-off to differentiate pharmacokinetic failure from pharmacodynamic 
failure needs to be defined, while for patients on maintenance therapy defining a 
therapeutic range with an upper and lower limit allows dose titration. An upper limit of 
the therapeutic range allows for dose de-escalation and cost saving without negatively 
impacting clinical outcome. Methods to define the lower limit of a therapeutic range 
include concentration quartiles, validation of a pre-determined value, or using a 
Receiver Operator Characteristic (ROC) curve. The latter has the advantage of 
allowing a trough level cut-off with optimal sensitivity and specificity for a given 
treatment endpoint to be selected. The upper limit of a therapeutic range may similarly 
be determined using concentrations quartiles, validation of a pre-determined value, or 
using a population concentration-response curve. The later method more precisely 
defines a drug trough level above which the proportion of patients achieving the 
chosen endpoint plateaus. Although several algorithms apply a single therapeutic 
range for both active disease and clinical remission, it is an assumption that the 
minimal therapeutic cut-off to induce remission in patients with active disease is the 
same as the minimal therapeutic cut-off to maintain remission.[19, 43, 45, 63, 124]  
Choice of a therapeutic range for anti-TNF agents needs to consideration several 
factors. There is significant inter-individual variability in the anti-TNF drug trough level 
required for induction of remission, manifested as considerable overlap in infliximab 
and adalimumab trough concentrations between responders and non-responders.[45, 
138] In addition, a significant proportion of patients may never respond to an anti-TNF 
agent, regardless of the drug level achieved, and are classified as having 
pharmacodynamic failure. Due to this inter-individual variability and plateau in 
response, with each incremental increase in the minimal infliximab trough cut-off we 
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will recapture response in fewer additional patients. Selecting a higher anti-TNF drug 
concentration as the lower limit of the therapeutic range would result in higher overall 
treatment cost and more patients with anti-TNF resistant disease undergoing futile 
dose escalation before changing to more appropriate treatment. On the other hand, 
selecting a lower limit trough level that is too low risks failing to recapture response in 
patients who require a higher anti-TNF drug level for response. Using a TDM algorithm 
approach for patients with treatment failure to either infliximab and adalimumab, a 
patient with therapeutic trough levels is labelled as having anti-TNF resistant disease 
(i.e. pharmacodynamic failure) and should be switched out-of-class rather than to 
another anti-TNF drug.[19, 43, 45, 63] If a TDM algorithm is strictly followed, labelling 
a patient as a pharmacodynamic failure to any one anti-TNF drug would exclude that 
patient from the entire drug class. In some patients, it may be appropriate to trial dose 
escalation to a drug trough level close to or above the upper limit of the therapeutic 
range before discontinuing an anti-TNF drug. This may be appropriate for patients with 
active disease who have failed multiple lines of therapy and have few remaining 
options.  
 
3.5.1 Infliximab steady-state therapeutic trough level 
Higher mean/ median infliximab trough levels have been found among patients in 
remission compared to those with active disease.[118, 128, 131, 134, 173] More 
clinically useful studies have defined a therapeutic cut-off associated with response, 
either through use of ROC curves, comparing remission rates between trough level 
quartiles, or through validation of a pre-determined therapeutic cut-off.[19, 80, 82, 98, 
116, 118-137, 147, 174-176] Most of these studies are cross-sectional and few are 
prospective. The studied populations and endpoints assessed have varied 
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considerably, such that results cannot be easily combined. In studies among patients 
with UC and luminal CD, steady state infliximab trough level found to correlate with 
mucosal healing have ranged from 2.1 to 6μg/mL, for CRP response from 1.4 to 
6.4μg/mL, and clinical response/ remission from 0.5 to 6.65μg/mL (Appendix, Table 
4).[80, 82, 98, 116, 118-125, 127-137, 147] Similarly, the minimal infliximab trough 
cut-off recommended by various published TDM algorithms has varied from 3 to 
6μg/mL.[45, 63, 124]  
Meta-analysis by Moore et al. identified 7 studies that reported remission rates based 
on infliximab thresholds.[131] Taking a somewhat arbitrary infliximab trough cut off of 
> 2μg/mL, four studies allowed data to be pooled. An infliximab level > 2μg/mL was 
found to be associated with increased likely-hood of both clinical remission (relative 
risk (RR) = 2.9, 95%CI 1.8 - 4.7, P < 0.001) and endoscopic remission (RR = 3, 95%CI 
1.4 - 6.5, P = 0.004). Similarly, a retrospective cross-sectional study analysed 
infliximab levels and CRP in stored serum samples from 532 CD patients from four 
RCTs and cohort studies.[80] Mean CRP was found to be significantly lower in those 
with an Infliximab trough of ≥ 3μg/mL (1.50ng/mL versus 5.65ng/mL, P < 0.001).  
When considering infliximab therapeutic cut-offs for patients with active disease, the 
clinically relevant question is above what infliximab trough level should the patient be 
deemed to have anti-TNF resistant disease (i.e. pharmacodynamic failure) and 
abandon further trials of dose escalation. The literature search identified only one 
study that correlated infliximab trough level pre-dose escalation to remission status 
post-dose escalation. A retrospective analysis by Yanai et al. found a trough infliximab 
level ≥ 3.8 µg/mL to be 90% predictive of lack of clinical response to dose escalation 
(PPV 56%, negative predictive value (NPV) 51%).[82]  
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When selecting a therapeutic infliximab cut-off to allow dose optimisation among IBD 
patients in remission, studies that have defined a therapeutic cut-off predictive of future 
remission or response are more useful than cross-sectional studies that correlate drug 
levels to outcome at the same time point. Post-hoc analysis of the ACCENTI study 
found a week 14 trough level of ≥ 3.5μg/mL to correlate with increased rates of 
sustained clinical response at week 54 (OR = 3.5, 95%CI 1.1 - 11.4, AUROC = 
0.75).[98] Similarly a study of 85 UC patients on maintenance infliximab examined 
remission rates at week 54 based on infliximab trough quartiles at week 30.[118] 
Remission rates were significantly higher in the 2nd quartile for infliximab trough level 
(90.5%, level ≥ 3.5 to < 8.4µg/mL) compared to the 1st (53.4%, < 3.5µg/mL). No 
significant difference in remission rates between 2nd quartile and 3rd (≥ 8.4 to < 
16.7µg/mL) and 4th (≥ 16.7µg/mL). The above study by Adedokun et al. indicates that 
clinical remission rates plateau above an infliximab trough of around 8.4μg/mL, with 
minimal additional benefit above this level.[118]  
However, higher trough levels appear to be needed if the treatment endpoint is 
mucosal healing. In a retrospective cross-sectional study an infliximab level > 5μg/mL 
identified patients with mucosal healing with 85% specificity (AUROC = 0.75, P < 
0.0001), with minimal increases in mucosal healing rates above an infliximab trough 
of 8μg/mL.[124] The authors propose that maintaining patients in an infliximab range 
of 6 to 10μg/mL would achieve mucosal healing in 85-90% of patients. 
 
3.5.2 Adalimumab therapeutic levels 
Similarly for adalimumab, studies have used a range of endpoints to define a 
therapeutic cut-off.[82, 83, 97, 119, 124, 138-149, 176] Lower steady state trough 
levels have been found to correlate with clinical remission (3.6 to 5.85μg/mL) 
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compared to endoscopic remission (4.9 to 9.1μg/mL) or histologic remission 
(7.8μg/mL) (Appendix, Table 5). Unfortunately, again most studies have been cross-
sectional, with few prospective trials that correlate drug levels with future outcomes. 
As with infliximab, for patients with active disease on adalimumab it is clinically most 
useful to define a trough cut-off above which dose escalation becomes futile (i.e. 
pharmacodynamic failure), to identify early on patient that should be switched out-of-
class. Yanai et al. again found that a pre-dose escalation adalimumab trough ≥ 
4.5μg/mL was 90% specific for failure to respond to adalimumab dose escalation (PPV 
85%, NPV 39.5%).[82] In another longitudinal observational study, 82 IBD patients 
had TDM performed prior to empiric adalimumab dose escalation for treatment 
failure.[83] For patients with undetectable anti-drug antibodies, response to dose 
escalation was much higher among patients with trough adalimumab ≤ 4.9μg/mL than 
patients with levels > 4.9μg/mL (67% versus 29%, P < 0.01). 
Several studies have defined a suitable maintenance trough range for patients on 
adalimumab. A cross-sectional study found an adalimumab trough at week 14 > 
4.5μg/mL to be 90% predictive of remission or response.[41, 119] The upper limit of 
the maintenance therapeutic range for adalimumab steady-state trough levels is not 
as well defined. Post-hoc analysis of the Ulcerative colitis long-term remission and 
maintenance with adalimumab 2 (ULTRA2) study compared rates of response 
between adalimumab trough concentration quartiles among 258 UC patients.[44, 141] 
Remission rates were significantly higher among patients in quartile 2 (5 to 8.7μg/mL) 
and quartile 3 (8.7 to 11.7μg/mL) compared to quartile 1 (< 5µg/mL), and did not 
increase beyond quartile 3. This suggests clinical remission rates plateau above a 
trough of approximately 11.7μg/mL, at least for UC. However, these levels were taken 
at week 8 following induction and are not steady state trough levels. Studies in 
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psoriasis and rheumatoid arthritis have used a population concentration-response 
curve to define a trough of 7μg/mL and 8μg/mL, respectively, above which response 
plateaus.[177, 178] Based on this data, some laboratories in Australia use 8µg/mL as 
the upper limit of the therapeutic adalimumab trough range for IBD patients as 
well.[179]  
When the endpoint is mucosal healing, target trough levels again appear to be higher. 
A cross-sectional study identified an adalimumab trough level >7.1μg/mL to be 85% 
specific for mucosal healing in IBD, and mucosal healing rates plateau above 
12μg/mL.[124] Based on this data the authors estimate that titrating adalimumab to a 
trough level of 8 to 12μg/mL would achieve mucosal healing in 80 -90% of patients. 
However, Roblin et al. found a relatively lower adalimumab trough cut-off of 4.9μg/L 
as optimal for predicting mucosal healing (AUROC = 0.77, P = 0.005, likelihood ratio 
(LR) = 4.3, sensitivity = 66%, specificity = 85%).[142]  
 
3.5.3 Certolizumab and golimumab therapeutic levels   
There is less data on therapeutic cut offs for certolizumab and golimumab as these 
anti-TNF drugs are relatively new. Sandborn et al. demonstrated that clinical remission 
rates were significantly higher with increasing golimumab trough level quartiles among 
UC patients on maintenance therapy at weeks 30 and 54: 25.0% for quartile 1 (< 
1.63μg/mL), 31.6% for quartile 2 (≥ 1.63 to < 2.51μg/mL), 35.0% for quartile 3 (≥ 2.51 
to < 4.13μg/mL), and 59.0% for quartile 4 (≥ 4.13μg/mL).[180] Similarly Colombel et 
al. demonstrated a positive correlation in CD patients between week 8 certolizumab 
drug levels and rates of endoscopic response and remission at week 10  (for response 
P = 0.0016, AUROC = 0.69; for remission P = 0.0302,  AUROC = 0.70).[181] There is 
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however less data on what the optimal maintenance range for both golimumab and 
certolizumab should be.  
 
3.5.4 Different disease phenotypes 
Studies that compare trough levels for a response between UC and CD patients, as 
well as between different disease phenotypes, are lacking. Many studies restricted 
their patient population to only CD or UC, and most studies that measured trough 
levels among all IBD patients have not performed a CD and UC subgroup analysis.[80, 
82, 83, 97, 98, 116, 118-136, 138-147] One study found a higher infliximab trough 
level to be predictive of clinical remission in UC (≥ 6.26μg/mL, sensitivity 50.0%, 
specificity 87.9%) compared to CD (≥ 2.18μg/mL, sensitivity 67.4%, specificity 78.6%), 
however no statistical analysis was performed between the two groups. The 
therapeutic cut-off found by studies to be predictive of response or remission for 
infliximab has ranged from 0.5 to 7.3μg/mL in CD, and 0.9 to 7.19μg/mL in UC.[80, 98, 
118-123, 127-133, 174, 182]  For adalimumab, seven studies have identified a 
therapeutic trough cut-off in CD ranging from 3.6 to 5.9μg/mL, and only one study in 
UC patients found a trough cut-off of 5μg/mL to predict for clinical response.[82, 97, 
119, 138-141, 143] Overall, the therapeutic cut-off for both infliximab and adalimumab 
determined in the above studies overlap considerably for CD and UC patients.  
Currently data on appropriate therapeutic cut-offs for different CD phenotypes are 
lacking, including stricturing and fistulising. Recently a study of CD patients with 
perianal fistulising disease suggested higher infliximab trough levels are needed to 
bring about fistula healing compared to therapeutic cut-offs previously quoted for 
luminal disease.[183] The median infliximab trough level was significantly higher 
52 
 
among patients with fistula healing compared to those with active fistulas (17.8μg/mL 
versus 4.4μg/mL respectively, P < 0.0001). Overall rate of fistula healing in this study 
was 54%, and fistula healing rates increased with increasing infliximab trough level 
quartiles: 21% in quartile 1 (0 - 2.8μg/mL), 47% in quartile 2 (2.9 - 10.0μg/mL), 71% 
in quartile 3 (10.1 - 20.1μg/mL), 86% in quartile 4 (20.2 - 50μg/mL). The authors 
advise aiming for infliximab trough levels above 10 µg/mL in perianal fistulising CD, 
however there appears to be a 15% absolute benefit in fistula healing with infliximab 
trough levels above 20 µg/mL compared to those with trough levels above 
10µg/mL.[183, 184] Aiming for infliximab trough levels > 20µg/mL may be 
appropriate for patients with non-healing fistulas. Similarly, Davidov et al. found that 
week 2 and 6 infliximab induction trough levels of ≥ 9.25μg/mL and ≥ 7.25μg/mL 
respectively, were optimal at predicting fistula response (for week 2 AUROC = 0.942, 
P < 0.0001; for week 6 AUROC = 0.9, P = 0.001).[185] These studies might suggest 
that all patients with fistulising CD should be on higher infliximab doses, however an 
earlier RCT did not find a statistically significant difference between fistula response 
rates among patients treated with 5mg/kg versus 10mg/kg infliximab (68% versus 
38% respectively, P = 0.35).[186] Higher anti-TNF drug dose does not always equate 
to higher trough level as the elimination half live of anti-TNF drugs is varied based on 
both patient and disease factors as previously discussed. [152-158] 
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3.6 Effects of anti-drug antibodies  
Most ATI are directed against the murine variable region of the infliximab molecule as 
determined by neutralisation studies, while most ATA are expected to bind the much 
smaller hypervariable region of the all human adalimumab molecule.[78, 187] As a 
result ATA occur at lower rates to ATI, with detection rates of 24% and 46% 
respectively found by Steenholdt et al. after 12 months of anti-TNF drug treatment.[19-
21, 188] However anti-drug antibody detection rates vary between different assays 
and risk of anti-drug antibodies developing is reduced with concomitant use of an 
immunomodulator, avoiding interrupted therapy and possibly through maintaining 
trough drug levels in the therapeutic range.[41, 46, 70, 96, 97, 162] Rutgeerts et al. 
found much higher rates of ATI positivity at 1 year among IBD patients treated with 
episodic infliximab therapy compared to those treated with continuous therapy (28% 
in episodic treatment group, 9% in patients maintained on 5mg/kg every 8 weeks and 
6% in those maintained on 10mg/kg every 8 weeks, statistical significance between 
groups not reported).[189] Immunomodulator use reduces formation of anti-drug 
antibodies and no difference has been demonstrated between azathioprine or 
methotrexate.[190] In a study by Vermiere et al. ATI positivity among those on 
concomitant azathioprine (48%) or methotrexate (44%) was lower than patients not on 
an immunosupressant (73%, P < 0.001 compared to being on either methotrexate or 
azathioprine). 
Anti-drug antibodies interfere with the activity of anti-TNF drugs via two mechanisms: 
complexing with the drug and increasing its clearance, and/ or directly interfering with 
the anti-TNF drug binding TNF or exerting its effect.[69, 191] In experimental monkeys, 
co-administration of infliximab and a radiolabelled ATI resulted in rapid immune 
complex formation as observed via serial analysis of blood samples on high 
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performance liquid chromatography.[191] Further gamma imaging studies indicated 
that the immune complexes concentrate in the reticuloendothelial system within 24 
hours of co-administration, indicating accelerated drug clearance. Similarly in a human 
study, administration of radiolabelled infliximab to ATI positive patients resulted in 
increased concentration of the radiolabelled drug in the liver and spleen (i.e. the 
reticuloendothelial system) relative to ATI negative controls.[187, 192] In patient 
studies anti-drug antibodies are associated with low anti-TNF drug levels and loss of 
response.[132, 188, 193-195] In addition, in vitro reporter gene assays have 
demonstrated that ATI positive sera from infliximab treated patients directly neutralises 
the anti-TNF activity of infliximab compared to control sera.[69] Presence of anti-drug 
antibodies is strongly associated with loss of response to both infliximab and 
adalimumab, with meta-analysis by Steenhold et al. yielding a RR of 3.2 and 10.15 
respectively.[44, 194, 195]   
Anti-drug antibodies also increase risk of injection/ infusion reactions with anti-TNF 
drugs.[14, 19, 196] In a study of infliximab re-introduction following a drug holiday, 
detectable ATI just before the second or third infliximab induction dose, predicted for 
an infusion reaction (HR 7.7, 95%CI 1.88 - 31.3, P = 0.004).[197] Episodic infliximab 
treatment increases the risk of ATI and infusion reactions compared to continuous 
treatment. In one cohort study, episodic treatment was the only significant predictor of 
infliximab infusion reaction (OR 5, 95%CI 2 – 13, P < 0.001).[68] Another study found 
that high titres of anti-infliximab antibodies are associated with increased rate of 
infusion reactions, with concentrations ≥ 8μg/mL imparting a 2.40 RR (95%CI 1.65 - 
3.66, P < 0.001).[14] Although risk of infusion reactions increases with increasing anti-
drug antibody titres, there is no clear threshold, and most patients with ATI do not have 
an infusion reaction.[19] Also, lack of ATI prior to infliximab re-initiation following a drug 
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holiday did not predict for lack of reaction.[68] Interestingly in this study, 88% of 
infusion reactions following infliximab re-initiation occurred at the second infusion. It is 
not clear if an anti-TNF agent should be stopped in patients with detectable anti-drug 
antibodies on anti-TNF drug reintroduction but are otherwise responding.  
 
Figure 3: Effects of anti-drug antibodies on infliximab drug pharmacokinetics as 
measured with a drug-tolerant assay A) Patient with no anti-drug antibodies, B) 
Patient with low titres of anti-drug antibodies and detectable drug trough levels, C) 
Patient with low titres of anti-drug antibodies and undetectable drug trough levels, D) 
Patient with high anti-drug antibody titres. 
 
When an anti-TNF drug is administered in a patient with anti-drug antibodies, the drug 
forms complexes with the anti-drug antibodies and both are cleared from the 
circulation.[191, 198] This renders anti-drug antibodies undetectable even to drug-
tolerant assays (Figure 3). Following the infusion, as anti-drug antibody production 
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continues anti-drug antibody levels rise while anti-TNF drug levels fall. The rate at 
which drug levels fall to undetectable limits depends on the titre of anti-drug antibodies, 
the avidity of anti-drug antibody binding and reticuloendothelial function that clears 
antibody-antigen complexes. Baert et al. found that patients with ATI titres ≥ 8μg/mL 
equivalent had a significantly reduced duration of infliximab effect following a single 
dose (mean 35 days, 95%CI 28 - 42 days) compared to those with ATI titres < 8μg/mL 
equivalent (mean 71 days, 95%CI 57 - 88 days, P < 0.001).[14] There was no 
difference in duration of response to a single infliximab dose among patients with 
undetectable ATI and those with ATI titres < 8μg/mL equivalent. Also for adalimumab 
as ATA titres increase adalimumab trough levels reduce. In a study by Mazor et al. 
ATA titres of < 1.5, 1.5 – 3 and ≥ 3μg/mL equivalent were associated with median 
adalimumab trough level of 6.7, 3.7 and 0μg/mL respectively (P < 0.001).[140, 199] 
ATA titres ≥ 3μg/mL equivalent were strongly predictive of active CD with 98% 
specificity (95%CI 95.5% - 100%) and positive LR of 10.3 
Presence of anti-drug antibodies in patients failing anti-TNF therapy can also predict 
lack of response to dose escalation. In a retrospective study of 155 patients with loss 
of response to infliximab with undetectable drug levels and detectable ATI, change to 
another anti-TNF agent resulted in higher rates of complete or partial response when 
compared to dose escalation (92% versus 17%, P < 0.004).[43, 200] Similarly, in 
patients with secondary loss of response to adalimumab in the setting of sub-
therapeutic drug trough levels (defined as < 4.9μg/mL), those with detectable ATA 
have significantly lower rates of response to dose escalation than patients with 
undetectable anti-adalimumab antibodies (12% versus 67%, P < 0.01).[83] Contrary 
to this, a retrospective study by Pariente et al. demonstrated that dose intensification 
for patients with loss of response to infliximab from 8th weekly to 4th weekly, restored 
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response in 6/10 (60%) of patients with detectable anti-drug antibodies.[201] Similarly, 
in a small observational study dose escalation of infliximab was able to restore 
therapeutic drug levels in 2 out of 3 patients with low drug levels and detectable 
ATI.[154, 202] However, titres of anti-drug antibodies correlate better with lack of 
response to dose escalation than qualitative detection, and this may account in part 
for these seemingly conflicting results. In the study by Yanai et al., ATA titres > 4μg/mL 
equivalent and ATI titres > 9μg/mL equivalent were 90% specific for failure to respond 
to adalimumab and infliximab dose escalation respectively.[82] There was no 
difference in response to dose escalation between patients with absent and low titre 
ATI or ATA. Low anti-drug antibody titres often disappear following dose escalation, 
with restoration of therapeutic anti-TNF drug levels. Therapeutic anti-TNF drug trough 
levels may be restored even in presence of high titres of anti-drug antibodies, provided 
large enough or frequently enough drug doses are administered, but this might be an 
expensive means of clearing high anti-drug antibody titres and risks an injection/ 
infusion reaction.[19, 81]  
Anti-drug antibodies may also disappear following addition of an immunomodulator, 
as illustrated by case reports and observational studies.[43, 203, 204] Ben-Horin et al. 
reports of 5 patients with loss of response to infliximab with sub-therapeutic drug levels 
and ATI, in whom therapeutic drug levels and response were restored with the addition 
of an immunomodulator.[203] In another observational study of 17 IBD patients with 
secondary loss of response due to ATA while on adalimumab therapy, addition of an 
immunomodulator (thiopurine in 11 patients, methotrexate in 6 patients) was able to 
eliminate ATA, restore therapeutic drug levels and restore clinical response in 8 
patients (47%).[204] This is an uncontrolled study and ATA titres were not reported. It 
is unclear if addition of an immunomodulator can overcome high titre anti-drug 
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antibodies. Addition of an immunomodulator may also reduce clearance of anti-TNF 
drug via mechanisms independent of suppression of anti-drug antibodies, including 
reduction of inflammatory load and generalised suppression of antibody clearance by 
the reticuloendothelial system.[43, 162, 176, 203, 204] Interestingly, Drobne et al. 
showed that infliximab trough levels do not reduce following immunomodulator 
withdrawal for patients that had been on co-treatment for at least 6 months.[205] 
Anti-drug antibody transiency complicates interpretation of TDM results. Persistent 
anti-drug antibodies are associated with loss of response and poor recapture of 
response following dose escalation, while transient anti-drug antibodies are not.[19, 
175]  In addition false positive results may be misinterpreted as anti-drug antibody 
transiency.[19] In an observational study, those with persistent ATI had significantly 
lower response rates to dose escalation (16%) compared to patients with transient 
(69%) or undetectable (94%) ATI (P value between persistent ATI and no ATI < 
0.0001, P value between persistent ATI and transient ATI = 0.0028, P value between 
transient ATI and no ATI = NS).[19, 175] In one retrospective study, two thirds of 
patients with positive ATI with clinical response who were continued on infliximab, 
cleared the ATI, indicating that antibody transiency is a common issue.[206] In contrast 
ATA, more often tend to persist and are functionally active due to invariably 
undetectable adalimumab drug levels and a high rate of loss of response to 
adalimumab (OR as high as 67 for loss of response in some studies, P < 0.0001).[19-
21] It has been shown that persistence of ATI on two blood samples more than 2 
months apart predicts for loss of response (67% absolute risk) compared to patients 
with ATI detected in one or no blood samples (P = 0.01).[207] Rates of loss of 
response were not significantly different among those with ATI detected in one blood 
sample and those with persistently undetectable ATI. An initial high ATI titre (defined 
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as >20ng/mL) was associated with persistence of the ATI and loss of response (94% 
specificity, 22% sensitivity, LR = 3.39, AUROC = 0.59). In another observational study, 
patients who met criteria for clinical response, with detectable ATI and were continued 
on infliximab therapy, ATI disappeared in 65% after a median of 4 infusions.[19, 20, 
206] Interestingly ATI titres in this study did not differentiate transient and persistent 
anti-drug antibodies (median titres 52U/mL and 80U/mL respectively, P = 0.419).[206]  
Anti-drug antibodies are not cross-reactive between different anti-TNF agents, but are 
between biosimilars.[73] Presence of ATI prior to initialisation of adalimumab does not 
increase the risk of developing ATA, nor does it increase risk of adalimumab therapy 
discontinuation or need for dose escalation.[41, 208-210] Similarly in patients with 
ATA, a response can be recaptured on switching to infliximab in a good proportion of 
patients.[83]  
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3.7 TDM for non-anti-TNF biologics 
Evidence for TDM of non-anti-TNF biologic agents in IBD is more limited. Higher 
vedolizumab drug levels correlate both with higher rates of clinical and endoscopic 
remission in UC.[211, 212] A week 6 post-induction cross sectional study 
demonstrated increasing mucosal healing rates across vedolizumab concentration 
quartiles, with mucosal healing rates of 20.1%, 32.4%, 44.8% and 62.9% for quartiles 
1, 2, 3 and 4, respectively. A recently published prospective trial found that a week 6 
post induction vedolizumab level of < 19.0μg/mL to be predictive of requirement for 
dose escalation.[213] In this trial all patients with a week 6 vedolizumab trough level < 
19.0μg/mL who were dose escalated were in clinical remission within 4 weeks.  
Ustekinumab levels following both induction and maintenance treatment have also 
been associated with clinical remission.[214] Week 8 post induction, higher rates of 
clinical remission were observed for quartile 3 (range > 3.58 to ≤ 6.74μg/mL, 40.1% in 
remission) and 4 (> 6.74μg/mL, 39.5% in remission) than for patients in quartiles 1 (≤ 
1.64μg/mL, 29.1% in remission) and 2 (> 1.64 to ≤ 3.58μg/mL, 27.9% in remission). 
For patients achieving clinical remission following ustekinumab induction, trough 
levels at week 24 predict for maintained clinical remission, with 54.3% in clinical 
remission in quartile 1 compared to 84.4% in quartile 4 (statistical significance not 
reported in abstract). Also a study found a week 8 ustekinumab trough level > 
4.5μg/mL to be associated with endoscopic response (sensitivity 72.2%, specificity 
83.3%, P = 0.0006, AUROC = 0.782).[215] Similarly an ustekinumab trough > 5μg/mL 
has been associated with higher rates of CRP normalisation (63.6% vs 33%, P = 
0.024). Interestingly ustekinumab levels have not been shown to correlate with clinical 
response in psoriasis.[216] 
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4. RESULTS 
4.1 Consensus committee composition 
Following the initial steering committee meeting, invitations were sent to 26 consensus 
committee nominees. All but one nominee (25/26) accepted the invitation to 
participate. The composition of the final consensus committee was as follows: 18 
gastroenterologists from Australia (RL, SC, GM, JMA, SG, MG, DL, VK, CC, MW, MS, 
DVL, PL, JB, GRS, RB, RM, KV), 1 IBD registrar from Australia (NM), 2 international 
gastroenterologists (CS, MB), 1 international clinical pharmacologist (NVC), 1 local 
clinical pharmacists (PS), 1 local clinical pharmacologist (JM) and 1 local Immunologist 
(CT) (Appendix, Table 6). 
 
4.2 Literature search 
The formal literature search found a total of 53 papers which were assessed as 
relevant to answering at least one pre-determined clinical question (Table 2 and Figure 
4). An additional 87 papers and abstracts were obtained from searching the references 
section of selected articles, via searching abstracts from major international 
conferences and from panel members. The 140 abstracts and papers were distributed 
to the panel members following the first round of voting, along with an evidence 
summary (Appendix, Table 7).  
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Figure 4: Literature search flow diagram. 
 
 
4.3 Proposed consensus statements and voting results 
The initial draft of the consensus proposed by the steering committee consisted of 25 
statements (Appendix, Table 8). All 25 panellists completed the online first-round vote 
(Table 5). Following the first voting round 17/25 (68%) of the statements met criteria 
for consensus (≥ 80% of voters agreeing without or only minor reservation). 
Statements were modified and expanded (to 28 statements) following the first voting 
round based on feedback and voting results (Table 3). Again all 25 panellists 
participated in the second voting round which was distributed online. Following the 
second voting round 21/28 (75%) of statements met criteria for consensus. The third 
voting session was a face-to-face meeting held in Sydney (21 January 2017). It was 
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attended by 22 of the 25 committee members, with 3 absentees for personal reasons 
(SC, KV, MG). One additional committee member left before the conclusion of the 
face-to-face voting session, again for personal reasons (JM).  
In the third and final voting round, statements were modified, combined and spilt up to 
produce a final set of 24 statements that panellists voted on. Overall 22/24 (92%) of 
statements met criteria for consensus following voting (Table 3). Statements were 
reordered following the final voting round based on feedback from panellists, in order 
to produce a more readable consensus document (Appendix, Table 9). Statements 
defining scenarios for performing TDM of anti-TNF agents were moved to the 
beginning. Statements for non-anti-TNF biologics and future therapies remained at the 
end. There was significant correlation between the agreed NHMRC levels of evidence 
and grades of recommendation for each statement (Spearman’s ranked order 
correlation co-efficient = 0.544, P = 0.006). To add to the practicality of the document, 
two flow diagrams were produced to summarise the recommendations for TDM of anti-
TNF drugs in patients with symptoms of active disease and those in clinical remission 
(Figures 5 and 6).  
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Table 5: Results of first, second and third voting rounds. For each voting round 
percentages in green indicate statements that met criteria for a consensus (≥ 80% 
agree with no reservation (A) or only minor reservation (B)), while percentages in red 
indicate statements that did not meet criteria for a consensus. Statements in grey were 
modified, removed or combined in subsequent voting rounds, while statements in bold 
were voted on in the final voting round. Panellists reached agreement via discussion 
on the NHMRC level of evidence (LE) and grade of recommendation (GR) for each 
statement. High risk features refer to risk factors for disease relapse or risk factors for 
severe consequences in the event of relapse (see 4.4.4 Statement 4. Interpreting TDM 
results among patients in clinical remission on anti-TNF therapy). 
  First voting round Second voting round Third voting round LE GR 
No. (no. 
after re-
ordering 
statements 
following 
3rd round 
vote) 
Proposed consensus statement Breakdown A + B  Breakdown A + B  Breakdown A + B  
1. Target drug trough levels         
1a12 In patients with luminal disease we 
generally recommend a steady state 
trough infliximab level between 3.8 and 
8.4μg/mL. 
A= 12% (3/25) 80.0% A= 28% (7/25) 92%     
B= 68% (17/25) B= 64% (16/25)     
C= 12% (3/25)  C= 8% (2/25)      
D= 8% (2/25) D= 0% (0/25)      
E= 0% (0/25) E= 0% (0/25)      
F= 0% (0/25) F= 0% (0/25)      
   A= 29% (6/21) 
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1a3 
(5a) 
In patients with luminal disease we 
generally recommend a steady state 
trough infliximab level between 3 and 
8μg/mL. 
   B= 67% (14/21) 96% II B 
    C= 0% (0/21)    
   D= 5% (1/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
1b12 In patients with luminal disease we 
generally recommend a steady state 
adalimumab trough level between 4.9 
and 8.7μg/mL. 
 
A= 24% (6/25) 84% A= 32% (8/25) 92%     
B= 60% (15/25) B= 60% (15/25)     
C= 8% (2/25)  C= 4% (1/25)      
D=8% (2/25) D= 4% (1/25)      
E= 0% (0/25) E= 0% (0/25)      
F=0% (0/25) F= 0% (0/25)      
1b3 
(5b) 
In patients with luminal disease we 
generally recommend a steady state 
trough adalimumab level between 5 and 
12μg/mL. 
 
    A= 40% (8/20) 95% II C 
  B= 55% (11/20) 
    C= 5% (1/20)    
   D= 0% (0/20)    
   E= 0% (0/20)    
   F= 0% (0/20)    
1c1 In certain situations higher trough levels 
than the above ranges may be 
appropriate. 
A= 64% (16/25) 100%       
B= 36% (9/25)       
C=0% (0/25)        
D=0% (0/25)       
E=0% (0/25)       
F=0% (0/25)       
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1c23  
(5c) 
In certain situations higher or lower 
trough levels than the above ranges may 
be appropriate. 
  A= 92% (23/25) 96% A= 67% (14/21) 100% III-3 B 
  B= 4% (1/25) B= 33% (7/21) 
  C= 4% (1/25)  C= 0% (0/21)    
  D= 0% (0/25)  D= 0% (0/21)    
  E= 0% (0/25)  E= 0% (0/21)    
  F= 0% (0/25)  F= 0% (0/21)    
2. Interpreting anti-drug antibodies         
2a123  
(6a) 
When interpreting anti-drug antibodies, 
quantifying titres is clinically more useful 
than positive/ negative status. 
A=56% (14/25) 88% A= 64% (16/25) 96% A= 76% (16/21) 100% II B 
B= 32% (8/25) B= 32% (8/25) B= 24% (5/21) 
C= 4% (1/25)  C= 0% (0/25)  C= 0% (0/21)     
D= 4% (1/25)  D= 4% (1/25)  D= 0% (0/21)     
E= 0% (0/25)  E= 0% (0/25)  E= 0% (0/21)     
F=1% (0/25)  F= 0% (0/25)  F= 0% (0/21)     
2b12  When interpreting anti-drug antibodies, 
repeat testing is useful to determine if 
antibodies are transient or persistent 
before acting on a result, particularly for 
patients that meet criteria for clinical 
remission. 
A= 52% (13/25) 80% A= 72% (18/25) 92%     
B= 28% (7/25) B= 20% (5/25)     
C= 8% (2/25)  C= 4% (1/25)      
D= 12% (3/25) D= 0% (0/25)      
E= 0% (0/25) E= 4% (1/25)      
F=0% (0/25) F= 0% (0/25)      
2b3  
(6b) 
When interpreting anti-drug antibodies, 
repeat testing is useful to determine if 
antibodies are transient or persistent. 
    A= 57% (12/21) 100% II B 
  B= 43% (9/21)    
    C= 0% (0/21)    
   D= 0% (0/21)    
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   E= 0% (0/21)    
   F= 0% (0/21)     
3. Scenarios when anti-drug Ab levels 
and anti-TNF levels should be 
measured to help guide clinical 
decision making: 
        
3a1 Patients should have therapeutic drug 
monitoring performed when in steady 
state following induction therapy whether 
or not they achieve clinical remission. 
A= 28% (7/25) 44%       
B= 16% (4/25)       
C= 36% (9/25)        
D= 12% (3/25)       
E= 8% (2/25)       
F= 0% (0/25)       
3a2 Patients in clinical remission following 
anti-TNF therapy induction should have 
therapeutic drug monitoring performed 
when in steady state to allow dose 
optimisation. 
  A= 16% (4/25) 64%     
  B= 48% (12/25)     
  C= 24% (6/25)      
  D= 12% (3/25)      
  E= 0% (0/25)      
  F= 0% (0/25)      
3a3  
(1a) 
In patients in clinical remission following 
anti-TNF therapy induction, TDM should 
be considered to guide management. 
  
 
  A= 52% (11/21) 100% II C 
   B= 48% (10/21) 
  
 
  C= 0% (0/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
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3b2 Patients with primary non-response or 
secondary loss of response should have 
therapeutic drug monitoring performed in 
order to guide clinical decision making. 
  A= 80% (20/25) 96%     
  B= 16% (4/25)     
  C= 0% (0/25)      
  D= 0% (0/25)      
  E= 4% (1/25)      
  F= 0% (0/25)      
3b13  
(1b) 
Therapeutic drug monitoring can inform 
clinical decision making in patients with 
primary non-response 
  
 
  A= 76% (16/21) 100% III2 C 
   B= 24% (5/21) 
  
 
  C= 0% (0/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
3b13 
(1c) 
Therapeutic drug monitoring should be 
performed in patients with secondary loss 
of response to guide clinical decision 
making 
  
 
  A= 90% (19/21) 100% I B 
   B= 10% (2/21) 
  
 
  C= 0% (0/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
3c2 Patients maintained in clinical remission 
are suggested to have periodic testing 
performed at least every 12 months. 
  A= 28% (7/25) 60%     
  B= 32% (8/25)     
  C= 20% (5/25)      
  D= 16% (4/25)      
  E= 4% (1/25)      
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  F= 0% (0/25)      
3c3 
(1d) 
TDM should be considered periodically in 
patients in clinical remission if the results 
are likely to impact management. 
    A= 57% (12/21) 90% IV D 
   B= 33% (7/21) 
    C= 5% (1/21)    
    D= 5% (1/21)    
    E= 0% (0/21)    
    F= 0% (0/21)    
3d2 
(1e) 
Patients maintained in clinical remission 
in whom a drug holiday is contemplated, 
are suggested to have therapeutic drug 
monitoring along with other 
investigations to help guide this decision. 
  A= 52% (13/25) 84% A= 62% (13/21) 100% III2 C 
  B= 32% (8/25) B= 38%(8/21) 
  C= 4% (1/25)  C= 0% (0/21)    
  D= 8% (2/25)  D= 0% (0/21)    
  E= 0% (0/25)  E= 0% (0/21)    
  F= 4% (1/25)  F= 0% (0/21)    
3e12 Therapeutic drug monitoring should not 
be performed in scenarios where results 
will not influence clinical decisions. 
A= 52% (17/25) 84% A= 64% (16/25) 92%     
B= 32% (8/25)  B= 28% (7/25)     
C= 4% (1/25)  C= 8% (2/25)      
D= 12% (3/25)  D= 0% (0/25)      
E= 0% (0/25)  E= 0% (0/25)      
F= 0% (0/25)  F= 0% (0/25)      
4. Interpreting drug levels in patients 
with confirmed active inflammatory 
disease 
        
4a12 Patients with confirmed active 
inflammatory disease and therapeutic 
A= 44% (11/25) 88% A= 32% (8/25) 88% A= 48% (10/21) 91% III2 C 
B= 44% (11/25) B= 56% (14/25) B= 43% (9/21) 
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(3a) drug trough levels (suggests 
pharmacodynamic failure) should be 
switched out-of-class. 
C= 4% (1/25)  C= 4% (1/25)  C= 10% (2/21)    
D= 8% (2/25) D= 8% (2/25)  D= 0% (0/21)    
E= 0% (0/25) E= 0% (0/25)  E= 0% (0/21)    
F= 0% (0/25) F= 0% (0/25)  F= 0% (0/21)    
4b12 
 
Patients with confirmed active 
inflammatory disease and sub-
therapeutic drug trough levels & no 
detectable anti-drug antibodies (suggests 
non-immune mediated pharmacokinetic 
failure) should have compliance checked 
first, followed by dose escalation. 
A= 80% (20/25) 100% A= 88% (22/25) 92%     
B= 20% (5/25) B= 4% (1/25)     
C= 0% (0/25)  C= 4% (1/25)      
D= 0% (0/25) D= 4% (1/25)      
E= 0% (0/25) E= 0% (0/25)      
F= 0% (0/25) F= 0% (0/25)      
4b3 
(3b) 
Patients with confirmed active 
inflammatory disease, sub-therapeutic 
drug trough levels and no detectable 
anti-drug antibodies (suggests non-
immune mediated pharmacokinetic 
failure) should have compliance checked 
first, followed by dose escalation of the 
anti-TNF agent. Optimization/ 
introduction of an immunomodulator 
should be considered. 
    A= 81% (17/21) 100% III3 B 
   B= 19% (4/21) 
    C= 0% (0/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
4c23 
(3c) 
Patients with confirmed active 
inflammatory disease, sub-therapeutic 
drug trough levels and low titres of anti-
drug antibodies (suggests immune 
mediated pharmacokinetic failure) should 
have an immunomodulatory added/ 
optimised and/ or anti-TNF dose 
escalation. 
  A= 68% (17/25) 92% A= 52% (11/21) 100% III3 B 
  B= 24% (6/25) B= 48% (10/21) 
  C= 0% (0/25)  C= 0% (0/21)    
  D= 4% (1/25)  D= 0% (0/21)    
  E= 4% (1/25)  E= 0% (0/21)    
  F= 0% (0/25)  F= 0% (0/21)    
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4d12 Patients with confirmed active 
inflammatory disease and undetectable 
drug trough levels & high titres of anti-
drug antibodies (suggests immune 
mediated pharmacokinetic failure) should 
be switched within class. 
 
A= 52% (13/25) 96% A= 36% (9/25) 96%     
B= 44% (11/25) B= 60% (15/25)     
C= 4% (1/25)  C= 4% (1/25)      
D= 0% (0/25) D= 0% (0/25)      
E= 0% (0/25) E= 0% (0/25)      
F= 0% (0/25) F= 0% (0/25)      
4d3 
(3d) 
Patients with confirmed active 
inflammatory disease, sub-therapeutic 
drug trough levels and high titres of anti-
drug antibodies (suggests immune 
mediated pharmacokinetic failure) should 
be switched within class for secondary 
loss of response, or alternatively switched 
within class or switched out-of-class for 
primary non-response. 
    A= 62% (13/21) 100% III2 B 
  B= 38% (8/21) 
    C= 0% (0/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
5. Interpreting drug levels among 
patients in clinical remission: 
        
5a123 
(4a) 
Patients in clinical remission and 
therapeutic drug trough levels should be 
continued on the same dose. 
A= 60% (15/25) 100% A= 68% (17/25) 96% A= 67% (14/21) 100% II B 
B= 40% (10/25) B= 28% (7/25 B= 24% (5/21) 
C= 4% (0/25)  C= 4% (1/25)  C= 5% (1/21)    
D= 0% (0/25) D= 0% (0/25)  D= 5% (1/21)    
E= 0% (0/25) E= 0% (0/25)  E= 0% (0/21)    
F= 0% (0/25) F= 0% (0/25)  F= 0% (0/21)    
5b123 
(4b) 
Patients in clinical remission and with 
supra-therapeutic drug trough levels 
should be considered for dose reduction. 
A= 40% (10/25) 88% A= 56% (14/25) 96% A= 48% (10/21) 91% III1 B 
B= 48% (12/25) B= 40% (10/25) B= 43% (9/21) 
C= 8% (2/25)  C= 4% (1/25)  C= 10% (2/21)    
D= 4% (1/25) D= 0% (0/25)  D= 0% (0/21)    
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E= 0% (0/25) E= 0% (0/25)  E= 0% (0/21)    
F= 0% (0/25) F= 0% (0/25)  F= 0% (0/21)    
5c123 
(4c) 
Patients in clinical remission and with 
sub-therapeutic drug trough levels 
should be individually assessed for 
suitability for a drug holiday. 
A= 36% (9/25) 80% A= 52% (13/25) 84% A= 10% (2/21) 24% III3 C 
B= 44% (11/25) B= 32% (8/25) B= 14% (3/21) 
C= 8% (2/25)  C= 4% (1/25)  C= 24% (5/21)    
D= 8% (2/25) D= 8% (2/25)  D= 48% (10/21)    
E= 4% (1/25) E= 4% (1/25)  E= 5% (1/21)    
F= 0% (0/25) F= 0% (0/25)  F= 0% (0/21)    
5d12 Patients in clinical remission who are 
deemed not suitable for a drug holiday, 
and with sub-therapeutic drug trough 
levels & undetectable anti-drug 
antibodies should have dose escalation. 
A= 16% (4/25) 48% A= 32% (8/25) 56%     
B= 32% (8/25) B= 24% (6/25)     
C= 24% (6/25)  C= 8% (2/25)      
D= 24% (6/25) D= 36% (9/25)      
E= 0% (0/25) E= 0% (0/25)      
F= 4% (1/25) F= 0% (0/25)      
5d3 
(4d) 
Patients in clinical remission who have 
high risk features, sub-therapeutic drug 
trough levels and undetectable anti-drug 
antibodies should have optimisation or 
addition of an immunomodulator and /or 
dose escalation 
A= 16% (4/25) 48% A= 32% (8/25) 56% A= 24% (5/21) 95% III3 C 
B= 32% (8/25) B= 24% (6/25) B= 71% (15/21) 
C= 24% (6/25)  C= 8% (2/25)  C= 5%(1/21)    
D= 24% (6/25) D= 36% (9/25)  D= 0% (0/21)    
E= 0% (0/25) E= 0% (0/25)  E= 0% (0/21)    
F= 4% (1/25) F= 0% (0/25)  F= 0% (0/21)    
5e1 Patients in clinical remission who are 
deemed not suitable for a drug holiday, 
and with sub-therapeutic drug trough 
levels & low titres of anti-drug 
A= 24% (6/25) 64%       
B= 40% (10/25)       
C= 16% (4/25)        
73 
 
antibodies should have an 
immunomodulatory added/ optimised & 
dose escalation. 
D= 16% (4/25)       
E= 0% (0/25)       
F= 4% (1/25)       
5e2 Patients in clinical remission who are 
deemed not suitable for a drug holiday, 
and with sub-therapeutic drug trough 
levels & low titres of anti-drug 
antibodies should have an 
immunomodulatory added/ optimised 
&/or dose escalation. 
  A= 32% (8/25) 76%     
  B= 44% (11/25)     
  C= 12% (3/25)      
  D= 12% (3/25)      
  E= 0% (0/25)      
  F= 0% (0/25)      
5e3 
(4e) 
Patients in clinical remission who have 
high risk features, with sub-therapeutic 
drug trough levels and low titres of anti-
drug antibodies should have an 
immunomodulatory added/ optimised 
and/or dose escalation. 
    A= 62% (13/21) 100% III1 B 
   B= 38% (8/21) 
    C= 0% (0/21)    
    D= 0% (0/21)    
    E= 0% (0/21)    
    F= 0% (0/21)    
5f1 Patients in clinical remission who are 
deemed not suitable for a drug holiday, 
and with undetectable drug trough levels 
& high titres of anti-drug antibodies, 
should be switched within class. 
A= 8% (2/25) 52%       
B= 44% (11/25)       
C= 20% (5/25)        
D= 24% (6/25)       
E= 4% (1/25)       
F= 0% (0/25)       
5f2 Patients in clinical remission who are 
deemed not suitable for a drug holiday, 
and with undetectable drug trough levels 
  A= 20% (5/25) 68%     
  B= 48% (12/25)  
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& high titres of anti-drug antibodies, 
should have a trial of 
addition/optimisation of an 
immunomodulator to try to overcome 
anti drug-antibodies. If this fails or the 
patient develops active disease they 
should be switched within class. 
  C= 20% (5/25)      
  D= 8% (2/25)      
  E= 4% (1/25)      
  F= 0% (0/25)      
5f3 
(4f) 
Patients in clinical remission who have 
high risk features, with undetectable drug 
trough levels and persistently high titres 
of anti-drug antibodies, should be 
considered for switching within or out-
of-class. 
    A= 10% (2/21) 86% III2 C 
   B= 76% (16/21)    
    C= 10% (2/21)    
    D= 5% (1/21)    
    E= 0% (0/21)    
    F= 0% (0/21)    
6. General steps to take for patients 
with symptoms of clinically active 
disease on anti-TNF therapy along 
with therapeutic drug monitoring: 
        
6a12 Patients with symptoms of active disease 
on anti-TNF therapy should have active 
inflammatory disease confirmed via 
objective measures (endoscopy, radiology 
and/or biochemistry).  
 
A= 72% (18/25) 96% A= 84% (21/25) 88%     
B= 24% (6/25) B= 4% (1/25)     
C= 4% (1/25)  C= 0% (0/25)      
D= 0% (0/25) D= 8% (2/25)      
E= 0% (0/25) E= 4% (1/25)      
F= 0% (0/25) F= 0% (0/25)      
6b12 Patients with symptoms of active disease 
on anti-TNF therapy should have 
investigations to exclude 
alternate/concomitant causes of 
A= 76% (19/25) 92% A= 80% (20/25) 92%     
B= 16% (4/25) B= 12% (3/25)     
C= 4% (1/25)  C= 4% (1/25)      
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symptoms along with therapeutic drug 
monitoring. 
D= 4% (1/25) D= 4% (1/25)      
E= 0% (0/25) E= 0% (0/25)      
F= 0% (0/25)  F= 0% (0/25)      
6ab3 
(2) 
Patients with symptoms of active disease 
on anti-TNF therapy should have active 
inflammatory disease confirmed via 
objective measures (endoscopy, imaging, 
serum/ faecal biomarkers) and 
investigations to exclude alternative/ 
concomitant causes of symptoms, prior to 
change in therapy. 
    A= 81% (17/21) 100% III3 C 
  B= 19% (4/21)    
    C= 0% (0/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
6c12 Patients with confirmed active 
inflammatory disease on anti-TNF 
therapy should have other IBD 
medications/ immunosuppressants 
optimised along with performing 
therapeutic drug monitoring. 
A= 76% (19/25) 92% A= 84% (21/25) 92%     
B= 16% (4/25) B= 8% (2/25)     
C= 4% (1/25)  C= 4% (1/25)      
D= 4% (1/25) D= 0% (0/25)      
E= 0% (0/25) E= 4% (1/25)      
F= 0% (0/25)  F= 0% (0/25)      
7. Standards for therapeutic drug 
monitoring 
        
712 We recommend the use of a drug-
tolerant assay over a drug sensitive assay 
for measurement of anti-drug antibodies. 
A= 20% (5/25) 60% A= 36% (9/25) 64%     
B= 40% (10/25) B= 28% (7/25)     
C= 20% (5/25)  C= 8% (2/25)      
D= 8% (2/25) D= 20% (5/25)      
E= 4% (1/25) E= 0% (0/25)      
F= 8% (2/25) F= 8% (2/25)      
   A= 62% (13/21) 
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(6c) 
There is insufficient evidence to 
recommend a drug-tolerant assay for 
anti-drug antibody detection 
   B= 33% (7/21) 95% III1 C 
    C= 5% (1/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
8. TDM for non-anti-TNF biologics         
812 Due to lack of evidence on appropriate 
troughs associated with specific 
endpoints for non-anti-TNF biologic 
agents currently used in IBD, we cannot 
recommend routine use of therapeutic 
drug monitoring to guide clinical decision 
making. 
A= 40% (10/25) 72% A= 44% (11/25) 92%     
B= 32% (8/25) B= 48% (12/25)     
C= 8% (2/25)  C= 4% (1/25)      
D= 12% (3/25) D= 4% (1/25)      
E= 8% (2/25) E= 0% (0/25)      
F= 0% (0/25) F= 0% (0/25)      
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(7a) 
There is emerging evidence that trough 
levels of non-anti-TNF biological agents 
may be relevant to clinical endpoints. 
However, more longitudinal data are 
required before routine use of 
therapeutic drug monitoring to guide 
clinical decision making on the use of 
non-anti-TNF biological agents. 
    A= 67% (14/21) 96% IV D 
  B= 29% (6/21) 
    C= 5% (1/21)    
   D= 0% (0/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
9. Future directions         
912 Data on therapeutic drug monitoring 
should be available at time of registration 
for all future biologics. 
A= 64% (16/25) 68% A= 60% (15/25) 88%     
B= 4% (1/25) B= 28% (7/25)  
C= 8% (2/25)  C= 4% (1/25)      
D= 12% (3/25) D= 4% (1/25)      
77 
 
E= 4% (1/25) E= 0% (0/25)      
F= 8% (2/25) F= 4% (1/25)      
93   
(7b) 
Data on therapeutic drug monitoring 
should be available at time of registration 
for all future therapies. 
    A= 29% (6/21) 77% III1 B 
  B= 48% (10/21) 
    C= 19% (4/21)    
   D= 5% (1/21)    
   E= 0% (0/21)    
   F= 0% (0/21)    
 
Legend: 
A= agree without reservation 
B= agree with minor reservation 
C= agree with major reservation 
D= disagree with some reservation 
E= disagree without reservation 
F= reserved 
 
1 Statement featured in first round of voting 
2 Statement featured in second round of voting 
3 Statement featured in third round of voting 
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Figure 5: Therapeutic drug monitoring in patients with symptoms suggesting 
active disease while on anti-TNF therapy. ADA, anti-drug antibodies; IBS, irritable 
bowel syndrome; IMM, immunomodulator; TDM, therapeutic drug monitoring; TL, 
trough level. 
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Figure 6: Therapeutic drug monitoring for patients in clinical remission while 
on anti-TNF therapy. High risk features refer to risk factors for disease relapse or 
risk factors for severe consequences in the event of relapse (see 4.4.4 Statement 4. 
Interpreting TDM results among patients in clinical remission on anti-TNF therapy). 
ADA, anti-drug antibodies; IBS, irritable bowel syndrome; IMM, immunomodulator; 
TDM, therapeutic drug monitoring; TL, trough level. 
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4.4 Elaboration on individual statements 
Below statements are ordered as they appear in the final document (Appendix, Table 
9). 
 
4.4.1 Statement 1: Scenarios when TDM of anti-TNF agents should be performed 
1a. In patients in clinical remission following anti-TNF therapy induction, TDM should 
be considered to guide management.  
Sub-therapeutic adalimumab and infliximab drug levels are associated with increase 
future risk of developing anti-drug antibodies and disease relapse.[31, 41, 96-100] The 
risk of anti-drug antibodies increases with cumulative time spent at sub-therapeutic 
drug levels and most anti-drug antibodies develop in the first 12 months from starting 
anti-TNF drug therapy.[21, 41, 97, 100, 188, 217] TDM for patients who achieve 
remission following anti-TNF drug induction may identify patients with sub-therapeutic 
anti-TNF drug levels, and dose escalating such patients early may prevent future anti-
drug antibody formation and secondary loss of response. In addition, dose reducing 
patients with supra-therapeutic anti-TNF drug levels results in cost saving without 
worsening clinical outcomes.[43, 102, 218] 
 
1b. Therapeutic drug monitoring can inform clinical decision making in patients with 
primary non-response 
Currently, most studies have assessed TDM in secondary loss of response to anti-
TNF drugs with relatively few studies assessing TDM-guided therapy in primary non-
response. [116, 138] TDM during primary non-response may still reveal if failure is 
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driven by inadequate drug levels (i.e. pharmacokinetic failure) or by anti-TNF resistant 
disease (i.e. pharmacodynamic failure), to guide appropriate treatment decisions. 
 
1c. Therapeutic drug monitoring should be performed in patients with secondary loss 
of response to guide clinical decision making 
TDM of anti-TNF drugs during secondary loss of response predicts for likelihood of 
response to various interventions: dose escalation, change within class or change out-
of-class.[82, 83] TDM-guided treatment following secondary loss of response to 
infliximab has also been shown to result in significant cost savings for up to 1 year 
compared to an empiric trial of dose escalation, despite equivalent clinical 
outcomes.[19, 41, 87, 90, 91] 
 
1d. TDM should be considered periodically in patients in clinical remission if the results 
are likely to impact management.  
Recommending a routine interval for repeating TDM for stable patients on ant-TNF 
therapy who are in remission is difficult. A regular testing interval needs to balance 
potential benefits against costs and the demands it places on health services. Vaughn 
et al. empirically recommends repeating proactive TDM every 6 to 12 months.[63] In 
the TAXIT study TDM-guided dose adjustment was performed every infusion 
cycle.[102] Despite this intensity of dose adjustment there was only benefit in the 
secondary endpoint of reduced need for rescue treatment. These benefits were not 
replicated in the more recent TAILORIX trial.[103] Given the mixed evidence of 
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benefits of routine proactive TDM for anti-TNF agents, the committee could not 
recommend a routine TDM interval for patients in remission. 
 
1e. Patients maintained in clinical remission in whom a drug holiday is contemplated, 
are suggested to have therapeutic drug monitoring along with other investigations to 
help guide this decision 
Some TDM algorithms assume IBD patient in remission should be continued on 
biologic therapy, and fail to consider the possibility of a drug holiday.[45, 63] The 
decision for an anti-TNF drug holiday should be individualised and take into account 
the risk of relapse, potential consequences of relapse, likelihood of recapture of 
response on anti-TNF drug re-introduction and risk of drug reactions with interrupted 
therapy. TDM results can form part of an algorithm to select patients for a drug holiday 
with low relapse risk. Maintained remission on anti-TNF therapy despite sub-
therapeutic trough levels may be explained by adequate anti-TNF drug exposure at 
other points of the dosing cycle, an individual with lower drug requirement, sub-clinical 
impending loss of response, or disease remission no longer dependent on anti-TNF 
drug exposure. The former two may be the case with levels slightly below the 
therapeutic range, however the latter two appear more plausible if drug levels are very 
low or undetectable. Maintained remission despite persistently very low or 
undetectable anti-TNF drug levels on repeat measurements several months apart may 
increase confidence that the particular patient will remain in remission on anti-TNF 
drug withdrawal.    
For patients in clinical remission, studies indicate that sub-therapeutic anti-TNF trough 
levels are predictive of sustained clinical remission following cessation of anti-TNF 
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therapy.[182, 219-221] Ben-Horin et al. found those with undetectable anti-TNF drug 
trough levels on cessation had much higher 12 month relapse free survival compared 
to patients with detectable drug levels (83% versus 14%, OR 30, 95%CI 5.8 - 153, P 
< 0.001).[219, 220] Similarly the study of infliximab diSconTinuation in CrOhn’s 
disease patients in stable Remission on combined therapy with Immunosuppressors 
(STORI) trial found that infliximab trough levels ≥ 2μg/mL were predictive of relapse 
following drug discontinuation (OR 2.5, 95%CI 1.1 – 5.4).[221] Other factors that 
predict for relapse following anti-TNF discontinuation include recent corticosteroid use, 
prior surgical resection, male sex, active smoker, lack of endoscopic remission and 
biochemical evidence of active inflammation (raised white cell count, CRP, faecal 
calprotectin, low haemoglobin).[221-225] A meta-analysis found that risk of relapse 
following anti-TNF withdrawal in CD at 1 year is 42% for patient in clinical remission, 
and 26% for those who were also in endoscopic remission prior to anti-TNF drug 
discontinuation.[222] 
Patients in whom the potential consequences of relapse are high may not be suitable 
for a drug holiday despite being at low risk of relapse. Patients with prior history of 
aggressive disease who have failed multiple lines of therapy, have had bowel 
resections and are at-risk of short gut syndrome in the event of further disease flares 
are unlikely to be suitable for a drug holiday. Interruptions in treatment with an anti-
TNF drug is associated with increased risk of anti-drug antibody formation, a major 
risk factor for loss of response and drug reactions.[14, 19, 44, 101, 194-197, 226] 
However most ATI and ATA develop within 12 months, and patients that are 
maintained on anti-TNF therapy beyond this period are much less likely to develop 
anti-drug antibodies.[21, 188, 217] This accounts for the high infliximab retreatment 
response rates in the STORI trial among patients who relapsed following drug 
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withdrawal (98% clinical response rate and 88% clinical remission rate assessed just 
before the third infusion).[217, 221] In the STORI trial all patients were on infliximab 
for more than 12 months before treatment discontinuation (mean duration 2.2 years, 
range 1.5-3.1 years). 
 
4.4.2 Statement 2. General approach to patients with symptoms of active 
disease on anti-TNF therapy 
2. Patients with symptoms of active disease on anti-TNF therapy should have active 
inflammatory disease confirmed via objective measures (endoscopy, imaging, 
serum/ faecal biomarkers) and investigations to exclude alternative/ concomitant 
causes of symptoms, prior to change in therapy. 
For IBD patients on anti-TNF drug treatment and bowel symptoms suggesting 
treatment failure, active inflammatory disease should be confirmed via objective 
measures.[227] Some treatment algorithms advocate performing TDM as part of the 
initial work up for patients on anti-TNF therapy with clinical relapse.[228, 229] The 
main intention with this approach is to reduce the number of unnecessary 
endoscopies. If sub-therapeutic anti-TNF drug levels are found a trial of dose 
escalation would be the next step, and endoscopy would be reserved for symptomatic 
patient with therapeutic anti-TNF drug levels in order to exclude alternative causes of 
bowel symptoms before changing therapy. In one study 62% of patients with bowel 
symptoms in the setting of therapeutic drug levels and no anti-drug antibodies had no 
objective evidence of inflammation on endoscopy or imaging.[43, 200] Symptoms in 
such patients may be secondary to a fibrotic stricture, bile salt malabsorption, 
malignancy, small bowel bacterial overgrowth or overlapping irritable bowel syndrome 
(IBS).[43] However anti-TNF drugs are expensive (e.g. cost of treating an 80kg patient 
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with standard infliximab doses over a 1 year period is over AU$14,000 for the drug 
alone) and the committee felt that active disease should be objectively confirmed prior 
to altering dosing or changing treatment in all symptomatic patients.  
Prevalence rates of IBS among patients with IBD have been reported to be 40-60%, 
which are 4-5 times higher than rates in the general population.[230-238] It has been 
postulated that IBD may predispose to development of IBS either directly through 
functional changes in the gut, or indirectly due to chronic illness-related anxiety.[238] 
In the general population, where rates of IBS are much higher compared to rates of 
IBD, a normal faecal calprotectin and CRP are very good at excluding IBD in those 
presenting with bowel symptoms.[238, 239] The utility of faecal calprotectin in 
diagnosing concomitant IBS in patients with prior diagnosis of IBD is less clear, 
however Quingley et al. recommends that young IBD patients with a normal faecal 
calprotectin be given a trial of IBS treatment prior to further investigations or changing 
IBD treatment.[238]  
The choice of imaging, endoscopy or inflammatory biomarkers for confirming active 
inflammation needs to be decided on an individual basis, considering factors such as 
the reliability of inflammatory biomarkers, disease location, exposure to ionising 
radiation and risks of performing an endoscopy. A meta-analysis found CRP to have 
sensitivity of 49% (95%CI 34% - 64%) and specificity of 92% (95%CI 72% - 96%) for 
detecting active inflammatory disease in IBD, while faecal calprotectin had a sensitivity 
of 88% (95%CI 84 - 90%) and specificity of 73% (95%CI 66 - 79%).[240] In this meta-
analysis faecal calprotectin was found to be more sensitive than CRP, and also faecal 
calprotectin was more sensitive in UC than CD.[240] Although faecal calprotectin 
correlates with active small bowel CD, its sensitivity is less than that for colonic 
IBD.[241, 242] Furthermore faecal calprotectin has not been validated in CD patients 
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with isolated involvement of the proximal ileum.[243] On an individual basis, there are 
patients in whom faecal calprotectin correlates poorly with disease activity, and so the 
STRIDE committee advised caution in use of inflammatory biomarkers as an endpoint 
to treatment.[60, 244] It may be prudent to first confirm the utility of faecal calprotectin 
within an individual patient by documenting a high level during times of endoscopically 
or radiologically confirmed active inflammatory disease, and normalisation during 
times of endoscopic or radiologic remission. 
Among patients with symptoms of active disease and objectively confirmed active 
inflammation, alternative and/or contributing causes of bowel inflammation should also 
be considered.  Clinically, non-IBD causes of colitis such as infection, ischemia or 
radiation, may present identical to IBD-related colitis. Clostridium difficile and 
Cytomegalovirus (CMV) colitis are relatively common among IBD patients and may 
mimic or exacerbate an IBD flare. Prevalence rates of C. difificile infection are higher 
among UC (37.3 per 1,000, 95%CI 34.0 - 40.7 per 1,000) and CD patients (10.9 per 
1,000, 95%CI 9.9 - 12.0 per 1,000) than non-IBD gastrointestinal patients (4.8 per 
1,000, 95%CI 4.6 - 5.0 per 1,000).[245] Compared to non-IBD patients where > 90% 
of C. difficile is associated with hospitalisation and antibiotic use, an observational 
study found that < 50% of IBD patients with C. difficile infection have these classic risk 
factors.[246] In one retrospective study concurrent CMV colitis was diagnosed in 
33.6% of patients with ASUC based on tissue histopathology or 
immunohistochemistry.[247]  
 
4.4.3 Statement 3. Interpreting TDM results in patients with confirmed active 
inflammatory disease on anti-TNF therapy 
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For patients with objectively confirmed anti-TNF treatment failure (primary non-
response or secondary loss of response), TDM may help elicit mechanisms of failure 
to help guide treatment decisions (Figure 5).[248]  
 
3a. Patients with confirmed active inflammatory disease and therapeutic drug trough 
levels (suggests pharmacodynamic failure) should be switched out-of-class. 
Patients with objectively confirmed active disease, in the setting of therapeutic trough 
levels of anti-TNF agent (i.e. phamracodynamic failure), likely have TNF-resistant 
disease. As previously outlined, pre-intervention therapeutic infliximab and 
adalimumab trough levels predicts for lack of recapture of response with dose 
escalation, or with switching to another anti-TNF drug.[43, 82, 83] Due to large inter-
individual variability in the minimal anti-TNF drug level required for response, a 
proportion of patients with treatment failure and trough levels at the lower end of the 
therapeutic range may still benefit from dose intensification. This may be considered 
for patients who have failed multiple lines of therapy and lack other treatment options. 
 
3b. Patients with confirmed active inflammatory disease, sub-therapeutic drug trough 
levels and no detectable anti-drug antibodies (suggests non-immune mediated 
pharmacokinetic failure) should have adherence checked first followed by dose 
escalation of the anti-TNF agent. Optimization/ introduction of an immunomodulator 
should be considered.  
Absence of anti-drug antibodies in patients with sub-therapeutic drug levels and active 
disease (i.e. non-immune mediated pharmacokinetic failure) predicts for response to 
88 
 
dose escalation to both infliximab and adalimumab.[43, 82, 83, 200] Roblin et al. 
demonstrated that patients with secondary loss of response to adalimumab, and sub-
therapeutic drug levels (<4.9μg/mL) had higher response rates on switching to 
infliximab compared to patients with therapeutic trough levels (80% versus 6.9%, 
P<0.01).[83] This enriches the earlier group with patients with anti-TNF responsive 
disease, and these patients may have also responded to adalimumab dose escalation 
provided therapeutic trough levels were achieved. Although patients with treatment 
failure and sub-therapeutic anti-TNF drug levels (i.e. pharmacokinetic failure) may 
respond to either dose escalation or switching to another anti-TNF agent, completely 
exhausting one biologic before switching to another is wise in the current era of limited 
biologic options.[176] Interestingly, Afif et al. found that dose intensifying patients with 
undetectable infliximab levels and no ATI resulted in higher response rates than 
switching to adalimumab (86% versus 33%, P < 0.016).[43, 200] Yanai et al. similarly 
found that patients with sub-therapeutic infliximab or adalimumab drug levels with 
absent or only low titre anti-drug antibodies had higher response rates with dose 
escalation rather than switching to another anti-TNF agent.[82] A significant proportion 
of patients with non-immune pharmacokinetic failure to an anti-TNF drug may have a 
generally increased clearance of all anti-TNF monoclonal antibodies, due to genetic 
polymorphisms or increased inflammatory load.[48, 159, 160, 164] This may explain 
the greater response rates observed with dose escalation compared to switching 
within class among such patients.  
Dose escalation for patients with non-immune mediated pharmacokinetic failure can 
be performed by increasing the dose per administration or reducing the dosing interval. 
In a retrospective study of patients with secondary loss of response to infliximab, there 
was no difference in remission rates between patients whose dose was doubled 
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versus those whose infusion interval was halved.[43, 249] The authors recommend 
increasing the dose per infusion for most to save on healthcare costs and resources 
associated with increased number of infusions. However, patients with breakthrough 
symptoms near the end of their infusion cycle may benefit more from reducing the 
dosing interval.  
Following dose optimisation it is important to confirm therapeutic drug levels as 
restoration of therapeutic drug levels correlates with effective dose escalation.[31, 137] 
In one study a post dose optimisation trough of >4.05μg/mL was found to be predictive 
of clinical response at 12 months (AUROC = 0.648, sensitivity 60%, specificity 75%, 
P = 0.05), as well as CRP normalisation both after 6 (AUROC = 0.652, sensitivity 59%, 
specificity 77%, P = 0.05) and 12 months (AUROC = 0.677, sensitivity 59%, specificity 
80%, P = 0.02).[250] Alternatively patients with sub-therapeutic drug levels may also 
have overlying pharmacodynamic failure. However, this will be difficult to elicit till 
persistent active inflammation is demonstrated in the setting of therapeutic trough 
levels.  
Addition or optimisation of an immunomodulator should be considered for patients 
with non-immune mediated pharmacokinetic failure. Apart from directly supressing 
inflammation and improving disease control, it is postulated that this intervention may 
also increase anti-TNF drug levels through decrease in circulating TNF and 
reduction of anti-TNF drug clearance by the reticuloendothelial system.[43, 162, 176, 
203, 204]  
 
3c. Patients with confirmed active inflammatory disease, sub-therapeutic drug trough 
levels and low titres of anti-drug antibodies (suggests immune mediated 
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pharmacokinetic failure) should have an immunomodulatory added/ optimised and/or 
anti-TNF dose escalation. 
Among patients with anti-TNF treatment failure due to sub-therapeutic drug levels and 
anti-drug antibodies (i.e. immune-mediated pharmacokinetic failure), anti-drug 
antibody titres influence response to various interventions. Yenai et al. demonstrated 
that low titre anti-drug antibodies may be overcome with anti-TNF dose escalation to 
restore therapeutic levels and response.[43, 82] Case reports and observational 
studies indicate that addition of immunomodulator may also suppress anti-drug 
antibodies to restore anti-TNF drug levels and response.[43, 203, 204] 
Dose escalation  or addition of an immunomodulator may in some cases only 
transiently suppress anti-drug antibodies due to increased circulating anti-TNF drug 
binding and clearing anti-drug antibodies.[198] With time anti-drug antibody 
production may increase again with a fall in anti-TNF drug trough concentrations to 
sub-therapeutic levels. Repeat TDM to measure anti-TNF drug levels and anti-drug 
antibodies following dose escalation is important to ensure the intervention was 
successful in restoring therapeutic drug levels.  
 
3d. Patients with confirmed active inflammatory disease, undetectable drug trough 
levels and high titres of anti-drug antibodies (suggests immune mediated 
pharmacokinetic failure) should be switched within class for secondary loss of 
response, or alternatively switched within class or switched out-of-class for primary 
non-response. 
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Patients with anti-TNF treatment failure who have sub-therapeutic drug levels and high 
titre anti-drug antibodies, are unlikely to have therapeutic drug levels restored with 
dose escalation or addition of an immunomodulator. Yanai et al. found that such 
patients had longer duration of response when switched to another anti-TNF agent 
than when dose escalation (P = 0.03).[43, 82]  It should be noted that the study 
population was patients with secondary loss of response to infliximab or adalimumab 
who by definition have previously demonstrated anti-TNF responsive disease. Such 
patients who lose response and are found to have sub-therapeutic trough levels and 
high titre anti-drug antibodies are likely to respond when switched to another anti-TNF 
agent provided therapeutic levels are established. Patients with primary non-response 
with sub-therapeutic anti-TNF drug levels and high titre anti-drug antibodies, who have 
no prior documentation of anti-TNF responsive disease may equally be considered for 
switching within class or out-of-class. Although addition of an immunomodulator may 
overcome anti-drug antibodies, this may be only effective among those with low titre 
anti-drug antibodies, as high titre anti-drug antibodies are likely to persist.[207] Studies 
that correlate titre of anti-drug antibodies to restoration of therapeutic anti-TNF drug 
levels following addition of an immunomodulator are lacking. 
 
4.4.4 Statement 4. Interpreting TDM results among patients in clinical 
remission on anti-TNF therapy 
TDM can inform treatment decisions among IBD patients in clinical remission while on 
anti-TNF drug therapy (Figure 6). The below statements assume the patient is not 
considered for a biologic drug holiday due to some combination of high-risk features. 
High-risk features refer to both risk factors for disease relapse (recent corticosteroid 
use, elevated serum/stool biomarkers, active disease at endoscopy, shorter duration 
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of disease remission, prior surgical resection, current smoker status, male sex) and 
risk factors for severe consequences in the event of relapse (eg. risk factors for further 
bowel resections and short gut syndrome).[221-225]  
 
4a. Patients in clinical remission and therapeutic drug trough levels should be 
continued on the same dose. 
The above statement assumes the therapeutic range chosen is appropriate for the 
selected treatment endpoint of clinical remission. 
 
4b. Patients in clinical remission and with supra-therapeutic drug trough levels 
should be considered for dose reduction.  
TDM algorithms for patients responding to anti-TNF therapy generally recommend 
dose de-escalating patients with supra-therapeutic levels.[45, 63] Due to plateau of 
anti-TNF response at high trough levels, it is hopped this would reduce cost without 
worsening clinical outcomes.[124]  In the TAXIT study, de-escalate infliximab dose in 
patients with a supra-therapeutic trough level resulted in 28% drug cost reduction (P 
< 0.001) without statistically significant decrease in clinical remission rates in both 
CD (80.4% pre dose reduction to 89.4% post dose reduction, P = 0.3) and UC 
patients (85.0% pre dose reduction to 85.0% post dose reduction, P = 1.0).[43, 102] 
A recent pilot study assessed infliximab dose de-escalating among CD patients in 
clinical remission, supra-therapeutic levels (> 10μg/mL) and undetectable ATI.[218] 
All 10 dose de-escalated patients maintained a HBI of 0 during the 24 week follow up 
period. 
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4c. Patients in clinical remission and with sub-therapeutic drug trough levels should 
be individually assessed for suitability for a drug holiday (consensus not reached). 
There was a marked swing in voting against this statement in the third voting round, 
compared to the first and second voting rounds (24% agreed with no or only minor 
reservation in the third voting round as compared to 80% and 84% in the first and 
second voting rounds respectively). This came about as a result of discussion 
around of when a drug holiday should be considered.  Although TDM can help risk 
stratify patients planned for an anti-TNF drug holiday, an anti-TNF drug holiday 
should not be considered for a patient purely based on an unexpected finding of sub-
therapeutic drug trough levels during proactive TDM. The rejection of statement 4c 
was also so as to restrict the remaining statements in section 4 to high-risk patients 
that are not considered suitable for a biologic drug holiday. This is also in agreement 
with statement 1d, that a routine proactive TDM interval for patients in clinical 
remission is not recommended and that TDM should only be performed if results will 
alter management.  
 
4d. Patients in clinical remission who have high risk features, sub-therapeutic drug 
trough levels and undetectable anti-drug antibodies should have optimization or 
addition of an immunomodulator and/ or dose escalation  
Sub-therapeutic anti-TNF drug levels in absence of anti-drug antibodies increase the 
risk of future anti-drug antibody formation to both infliximab and adalimumab, and 
dose escalating these patients may prevent loss of response secondary to immune-
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mediated pharmacokinetic failure.[31, 41, 96-100, 132] In the optimisation phase of 
the TAXIT study, dose escalating patients on long-term infliximab maintenance with 
sub-therapeutic trough levels results in increased rate of remission (from 65.1% to 
88.4%, P = 0.02), and reduced median CRP (from 4.3mg/L to 3.2mg/L, P < 0.001) 
among CD patients.[43, 102] However no significant change was observed among 
UC patients. As discussed previously, addition of an immunomodulator may also 
increase anti-TNF drug levels  in patients without detectable anti-drug antibodies.[19]   
 
4e. Patients in clinical remission who have high risk features, with sub-therapeutic drug 
trough levels and low titres of anti-drug antibodies should have an immunomodulatory 
added/ optimised and/ or dose escalation.  
IBD patients in clinical remission with sub-therapeutic anti-TNF drug levels should 
have anti-drug antibodies measured in order to guide treatment decisions.[45, 63] 
Extrapolating from studies in patients with treatment failure to infliximab and 
adalimumab, dose escalation or addition of an immunomodulator can restore 
therapeutic drug levels in patients with low titre anti-drug antibodies.[43, 82, 203, 
204, 250] It is hoped this will prevent a future disease flare. Panellists could not 
reach agreement if in the first instance clinicians should attempt addition/ 
optimisation of an immunomodulator, anti-TNF drug dose escalation, or both, in 
order to elevate anti-TNF drug trough levels. There is no data directly comparing the 
effectiveness of these three potential interventions in elevating anti-TNF drug levels. 
Addition/ optimisation of an immunomodulator would be a relatively less expensive 
intervention than anti-TNF drug dose escalation. On the other hand, both dose 
escalating and adding/ optimising an immunomodulator in the first instance may 
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potentially be more effective at achieving therapeutic anti-TNF drug levels than either 
alone.  
 
4f. Patients in clinical remission who have high risk features, with undetectable drug 
trough levels and persistently high titres of anti-drug antibodies, should be 
considered for switching within or out-of-class.  
As discussed for patients with treatment failure on anti-TNF therapy, dose escalation 
or addition of an immunomodulator is unlikely to overcome high titres of anti-drug 
antibodies to restore therapeutic levels.[82, 207, 250]  In addition there is a concern 
for drug reactions with continued anti-TNF administration in patients with high titre anti-
drug antibodies.[14, 19, 196, 197] Although high titre anti-drug antibodies have been 
associated with persistence, there is overlap between titres of persistent and transient 
anti-drug antibodies.[19, 20, 206, 207] There may be less urgency to change treatment 
in asymptomatic patients, and repeating TDM first to exclude anti-drug antibody 
transiency may be worthwhile even among patients with high-titre anti-drug antibodies.  
 
4.4.5 Statement 5. Target drug trough levels 
These consensus statements are predominantly intended to aid gastroenterologists in 
Australia, so the treatment endpoints they are based on must be compatible with the 
current PBS system. Continuation of PBS subsidised biologic maintenance treatment 
in Australia depends on demonstrating ongoing adequate response every 24 weeks, 
as defined by several criteria (Table 1). These criteria emphasise clinical disease 
activity scores and do not include endoscopic remission. Despite endoscopic 
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remission being a more objective treatment endpoint associated with improved 
outcome over clinical remission alone, guidelines for TDM of anti-TNF agents based 
around endoscopic remission cannot easily be integrated with the currently PBS 
system.[60-62] As such appropriate steady state therapeutic ranges were determined 
for infliximab and adalimumab for clinical remission as the treatment endpoint.  
Most TDM data, particularly for adalimumab, are for luminal CD patients, however 
studies among UC patients have found similar cut-offs.[176] The committee agreed 
that the defined therapeutic ranges for adalimumab and infliximab should be applied 
with a degree of caution to UC patients. Due to measurement error, it was agreed to 
round off the upper and lower limits of the proposed therapeutic ranges to whole 
numbers.  
 
5a. In patients with luminal disease we generally recommend a steady state trough 
infliximab level between 3 and 8μg/mL.  
Studies that determined a steady state therapeutic cut-off or range for infliximab 
among IBD patients with luminal disease were considered (Appendix, Table 4).[80, 
82, 98, 116, 118-137, 147, 174-176] The agreed therapeutic range for infliximab (3 to 
8µg/mL) was similar to prospective studies by Steenholdt et al. and Vande Casteele 
et al. which demonstrated cost saving and reduced disease flares respectively using 
a maintenance range of 3 to 7µg/mL.[19, 41, 87, 90, 102] Similarly Yenai et al. found 
a pre-dose escalation infliximab trough of ≥3.4µg/mL as optimal for predicting lack of 
response to dose escalation in secondary loss of response, while Adendokun et al. 
demonstrated that response to infliximab in UC plateaus above a trough of 
8.4µg/mL.[82, 118]  
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5b. In patients with luminal disease we generally recommend a steady state 
adalimumab trough level between 5 and 12 μg/mL. 
Similarly in selecting a therapeutic range for adalimumab among IBD patients with 
luminal disease, studies determining a steady state therapeutic cut-off or range were 
considered (Appendix, Table 5).[82, 83, 97, 119, 124, 138-147, 176] The lower limit 
of the determined adalimumab therapeutic range (5 to 12µg/mL) is based on studies 
by Yanai et al. and Echarri et al. which found a trough of > 4.5µg/mL to predict for 
lack of response to dose escalation in secondary loss of response as well as clinical 
response or remission among patients on maintenance therapy, respectively.[82, 
119] The upper limit of the adalimumab therapeutic range (12µg/mL) is based on 
endoscopic remission data, as data with clinical remission as the treatment endpoint 
are lacking.[124] This is significantly higher than an upper limit of 8µg/mL quoted by 
some laboratories in Australia, based largely on rheumatological data.[177-179]  
 
5c. In certain situations higher or lower trough levels than the above ranges may be 
appropriate. 
The above recommended therapeutic ranges for infliximab and adalimumab may 
need to be altered for different disease phenotypes or treatment endpoints. Higher 
infliximab trough levels have been found to be needed for fistula healing in peri-anal 
CD.[183, 185] Similarly, the therapeutic ranges to achieve endoscopic remission with 
infliximab or adalimumab appear to be higher than what is required for clinical 
remission.[124] 
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4.4.6 Statement 6. Anti-drug antibodies 
6a. When interpreting anti-drug antibodies, quantifying titres is clinically more useful 
than positive/ negative status.  
Qualitative detection of ATA and ATI is associated with sub-therapeutic drug trough 
levels, loss of response, and lack of recapture of response following dose 
escalation.[44, 83, 194, 195] However, quantification of anti-drug antibody titres 
rather than qualitative detection, is a better predictor of the above.[14, 82, 140, 199] 
Low titre anti-drug antibodies can often be overcome with dose escalation, and do 
not appear to reduce the likelihood of response as compared to patients with 
undetectable anti-drug antibodies.[82] Anti-drug antibody cut offs that distinguish 
anti-drug antibodies as low or high titre are assay specific. As previously discussed 
titres cannot easily be standardised between different assays.[20, 70, 71, 79] As 
such clinicians are advised to use an assay with an anti-drug antibody cut off that 
has been correlated with outcome data.   
 
6b. When interpreting anti-drug antibodies, repeat testing is useful to determine if 
antibodies are transient or persistent before acting on a result, particularly for patients 
that meet criteria for clinical remission.  
There is generally less urgency to alter treatment for patients in remission, and repeat 
TDM to differentiate transient and persistent anti-drug antibodies may be clinically 
useful. Transient anti-drug antibodies are relatively common, especially among 
patients who are responding to therapy, and are not associated with loss of 
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response.[19, 20, 188, 206] Repeat TDM to differentiate transient and persistent anti-
drug antibodies may be particularly useful in patients planned for a drug holiday, or in 
those planning to change to another treatment. The ideal time frame for repeating TDM 
in order to differentiate transient/ persistent anti-drug antibodies is not clear. Also, an 
initial finding of high titre anti-drug antibodies has not consistently been found to 
predict for anti-drug antibody persistence.[206, 207] In view of this, it may be prudent 
to repeat TDM in all patients in remission found to have sub-therapeutic anti-TNF drug 
levels and anti-drug antibodies regardless of titre, provided there is no urgency to 
change treatment before TDM results are available.  
 
6c. There is insufficient evidence to recommend a drug-tolerant assay for anti-drug 
antibody detection 
The ability of drug-tolerant anti-drug antibody assays to detect anti-drug antibodies in 
serum samples with free drug, has not translated to a clear clinical advantage over 
drug-sensitive assays. Anti-bodies detected in presence of free drug most often lack 
neutralising potential, while high titre anti-drug antibodies that are of clinical 
significance appear to be detected equally well by both drug-tolerant and drug-
sensitive assays.[71, 85] In addition, drug-tolerant assays are significantly more 
expensive and currently not available in Australia.  
 
4.4.7 Statement 7. TDM for non-anti-TNF biologics and future therapies 
7a. There is emerging evidence that trough levels of non-anti-TNF biological agents 
may be relevant to clinical endpoints. However, more longitudinal data are required 
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before routine use of therapeutic drug monitoring to guide clinical decision making on 
the use of non-anti-TNF biological agents. 
Cross-sectional studies have found that vedolizumab and ustekinumab drug levels are 
associated with clinical and endoscopic remission, and in the case of vedolizumab 
also need for dose escalation.[211-215] Mechanisms of treatment failure for non-anti-
TNF biologics are likely to be similar to anti-TNF biologics. Patients found to have 
therapeutic levels of a non-anti-TNF biologic drug (i.e. pharmacodynamic failure) are 
not likely to benefit from further dose escalation and should be changed to another 
biologic, where as those found to have sub-therapeutic drug levels and active disease 
(i.e. pharmacokinetic failure) would likely benefit from dose escalation provided anti-
drug antibodies are absent or present in only low titres. Anti-drug antibodies tend to 
occur at much lower rates with vedolizumab (0.4 – 1.0% at 52 weeks) and 
ustekinumab (2.3% at 52 weeks) as compared to treatment with anti-TNF 
biologics.[251-253] It is not clear if antibodies to vedolizumab or antibodies to 
ustekinumab can be overcome with dose escalation or addition of an 
immunomodulator in a similar fashion to anti-drug antibodies against anti-TNF drugs, 
and if anti-drug antibody titres influence ability to restore therapeutic drug levels with 
these interventions. 
 
7b. Data on therapeutic drug monitoring should be available at time of registration for 
all future therapies (consensus not reached). 
Although the majority of the consensus committee agreed that TDM data should 
accompany pivotal clinical studies of all future IBD drugs, consensus was not reached. 
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Several panellists felt that this recommendation is best left to regulatory bodies to 
endorse.  
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5. DISCUSSION 
IBD treatment currently is moving towards personalised therapy. Personalised therapy 
in IBD utilises various predictive and prognostic markers in order to optimise IBD 
treatment for individual patients. TDM of anti-TNF drugs is an important aspect of 
personalised IBD treatment currently being practiced. At the moment uptake of TDM-
guided anti-TNF therapy is variable among Australian gastroenterologists. Lack of 
awareness of when to perform TDM and how to act on results are potentially major 
barriers. These consensus statements should provide a practical guide to assist 
gastroenterologists in Australia and abroad in utilising TDM-guided anti-TNF therapy. 
Biologic drugs are expensive and treatment failure is a significant issue. TDM-guided 
anti-TNF therapy can better select patients with treatment failure who are likely to 
benefit from dose escalation, and identify patients who should be switched to other 
treatments earlier. This may avoid futile, empiric, dose escalation trials, allow effective 
treatment to be commenced sooner, and so reduce disease burden and treatment 
cost. Early dose optimisation in patients who achieve remission to anti-TNF drug 
induction may further reduce future disease flares, treatment failure secondary to anti-
drug antibody development, and treatment cost. Uptake of TDM-guided anti-TNF 
therapy among gastroenterologists is important to ensure benefits of these drugs are 
maximised.  
Recommendations around reactive TDM of anti-TNF agents were stronger compared 
to recommendations around proactive TDM, reflecting the current evidence. The panel 
could not recommend routine proactive TDM for patients who are in clinical remission 
beyond TDM-guided anti-TNF drug dose optimisation shortly following successful anti-
TNF induction. The recommendation for proactive TDM among patients in clinical 
103 
 
remission was to perform it only if results are likely to impact management. The level 
of evidence for this recommendation was low (IV), consequently attracting a low 
NHMRC grade of recommendation (D, Appendix, Tables 1, 2 and 3). Despite several 
observational studies, currently there is lack of high-quality evidence to guide 
treatment decisions for patients with anti-TNF treatment failure based on TDM results. 
RCTs are currently underway with adequate power to compare outcomes of different 
interventions (dose escalation, switching within class or switching out-of-class) 
between different treatment failure subgroups as defined by TDM (pharmacodynamic 
failure, immune-mediated pharmacokinetic failure, non-immune mediated 
pharmacokinetic failure).[19] 
Compared to the recently published consensus on TDM-guided anti-TNF therapy from 
the Building Research in Inflammatory Bowel Disease Globally (BRIDGe) group, these 
consensus statements have considerable similarities but also some notable 
differences.[31] The literature search which formed the basis of the BRIDGe group 
guidelines was completed in November 2013. Several important studies have since 
been published, particularly related to appropriate infliximab and adalimumab trough 
levels in luminal and peri-anal fistulising disease, as well as data on TDM of non-anti-
TNF biologics.[82, 97, 98, 116, 118, 119, 124, 130, 131, 133, 135, 147, 183, 185, 211-
216] Overall, our consensus statements were more applicable to clinical practice 
through the definition of therapeutic ranges, the inclusion of decision flow diagrams 
and through rating of the level of evidence and grade of recommendation for each 
consensus statement.  
There are several limitations to the therapeutic ranges for infliximab and adalimumab 
recommended by our consensus committee. The agreed therapeutic ranges are for 
luminal disease and for clinical remission as the treatment endpoint. Despite the 
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emphasis on clinical scoring tools in PBS criteria for initiation and continuation of 
biologic treatment in Australia, panel members agreed that endoscopic and/or 
histologic remission are better treatment endpoint than clinical remission, in line with 
evidence for improved rates of steroid-free remission among CD patients and 
reduction in colorectal cancer among UC patients.[29, 30, 60-62] Although the 
committee acknowledged that evidence indicates higher anti-TNF drug levels are 
required for endoscopic remission and to heal fistulising disease, it did not make 
recommendations about appropriate ranges for these two scenarios.[124, 126, 183] 
Also, the committee felt that most TDM data are in CD, particularly for adalimumab, 
and the determined therapeutic ranges should be applied with greater caution to UC 
patients. For example, in the study by Ungar et al. only 14% of the included IBD 
patients had UC as their diagnosis, and subgroup analysis was not attempted.[124] 
Due to relatively little data, our consensus committee did not define appropriate 
adalimumab and infliximab levels taken during induction treatment (i.e. not in steady 
state) or at other parts of the dosing cycle.[116-118, 143, 171, 172] Although our 
consensus committee agreed that TDM of anti-TNF agents may elicit mechanisms of 
failure in primary non-response so as to guide treatment decisions, by not defining 
appropriate induction therapeutic ranges, readers of these consensus statements 
cannot easily differentiate mechanisms of failure in this setting (i.e. pharmacodynamic 
versus pharmacokinetic failure) unless drug levels are found to be very high or very 
low. This detracts somewhat from the clinical applicability of these consensus 
statements. The consensus statements focused on TDM for infliximab and 
adalimumab, and did not make recommendations about appropriate therapeutic 
ranges for anti-TNF drugs used to treat IBD that are currently not available in Australia, 
golimumab and certolizumab. Although similar TDM-decision algorithms can be 
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applied for golimumab and certolizumab, TDM data defining appropriate therapeutic 
ranges for these anti-TNF agents are limited to smaller cross-sectional studies.[180, 
181] 
A further limitation to the current guidelines relates to difficulty in defining anti-drug 
antibody titre cut-offs as high and low. Such cut-offs are assay specific and differences 
in assays cannot be easily adjusted owing to different sensitivity of assays for different 
antibody subtypes, and the vastly varied proportion of such subtypes in anti-drug 
antibody positive serum samples.[20, 70, 79] Despite universal standardisation for 
anti-drug antibody detection being proposed, similar to the international ratio (INR) 
used to standardise pro-thrombin time (PT) measured across different laboratories, 
the former scenario is more complex.[78] The treatment algorithms derived from the 
consensus statements (Figures 5 and 6) rely on anti-TNF titres to be quantified, and 
for the anti-drug antibody assay used to have validated cut-offs for differentiating low 
and high titres. Some laboratories in Australia qualitatively report anti-drug antibodies 
as present or absent, making these two algorithms more difficult to apply in cases 
where anti-drug antibodies are positive. Similarly, the algorithms were based around 
drug-sensitive assays and did not consider detectable anti-drug antibodies in the 
setting of therapeutic anti-TNF drug levels. This scenario is specific for drug-tolerant 
assays which are not currently available in Australia, are considerably more 
expensive, and do not appear to offer an advantage clinically.[71, 81, 84, 85] 
The BRIDGe group consensus described TDM in five patient groups: 1) primary non-
responders following induction, 2) patients with secondary loss of response, 3) 
responders following induction therapy, 4) responders during maintenance therapy 
and 5) patients undergoing anti-TNF re-introduction following a drug holiday.[31] The 
BRIDGe group could not reach agreement in recommending routine TDM for 
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responders following induction, however recommended TDM be performed within the 
first 12 months of successful induction. Our consensus panel recommended TDM in 
similar scenarios, but with some exceptions. Our committee felt it was appropriate to 
perform TDM shortly following successful anti-TNF drug induction, to allow dose 
optimisation and reduce future risk of anti-drug antibody development and subsequent 
loss of response.[41, 43, 97, 100] Also, unlike the BRIDGe consensus our panel 
considered and recommended TDM as part of the assessment for patients planned 
for an anti-TNF drug holiday to help stratify relapse risk. This is based on studies 
indicating sub-therapeutic anti-TNF drug levels predict for sustained remission 
following anti-TNF withdrawal.[219, 221] Unlike the BRIDGe group our panel did not 
consider TDM for patients on re-introduction of an anti-TNF agent post drug holiday, 
to stratify risk of infusion reactions. Although anti-drug antibodies are a risk factor for 
drug reactions, transient anti-drug antibodies on anti-TNF drug reintroduction are 
common, most patients with detectable anti-drug antibodies do not have a reaction, 
titres of anti-drug antibodies have not consistently predicted for likelihood of reaction, 
and absence of anti-drug antibodies does not predict for lack of reaction.[14, 19, 20, 
68, 196, 206] Discontinuing patients with anti-drug antibodies following anti-TNF drug 
re-introduction who are otherwise responding, may result in more futile treatment 
changes than prevented drug reactions. Overall, TDM on anti-TNF drug reintroduction 
may not be useful in avoiding drug reactions. TDM of anti-TNF drugs during pregnancy 
was not considered by neither our consensus committee nor the BRIDGe group 
consensus. Data are lacking on what are optimal drug levels in pregnant women to 
balance the benefits of disease control against the risks of anti-TNF drug exposure for 
newborn infants. 
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Our consensus committee considered TDM for non-anti-TNF biologics, namely 
vedolizumab and ustekinumab, but this could not be recommended in routine clinical 
practice due to relatively little data.[211-216] More studies are required to confirm that 
the similar TDM principles apply for non-anti-TNF biologics, to define appropriate 
therapeutic ranges to differentiate pharmacokinetic and pharmacodynamic failure, and 
to determine if anti-drug antibodies can be overcome with dose escalation or addition 
of an immunomodulators and whether anti-drug antibody titres influence response to 
these interventions. Currently assays to measure drug levels and anti-drug antibodies 
for non-anti-TNF biologics are not available for routine clinical use in Australia. 
Although vedolizumab can be dose escalated via compassionate access in Australia, 
this is currently not within the Therapeutic Goods Administration (TGA) label. Only 
300mg IV every 8 weeks is on the TGA label and not 300mg IV every 4 weeks. 
However, the pivotal data indicate that incremental therapeutic gain can be achieved 
with dose interval decrease.   
Although cost saving is a potential benefit of following these guidelines, there was no 
separate statements dealing with cost saving. These consensus statements are 
intended for clinicians rather than policy makers. As such they primarily provide 
recommendations around when to perform TDM of anti-TNF agents and how to act on 
results. Although not specifically stated within the body of statements 3a-d and 4a-f, 
the aim of each TDM-guided intervention is either improvement in clinical outcomes or 
cost saving. 
6. CONCLUSION 
To conclude, TDM of anti-TNF drugs is an important aspect of personalised IBD 
therapy that aims to maximise benefit and reduce treatment cost with these agents. 
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These consensus statements are intended to act as a practical guide for use of TDM 
in optimising IBD treatment, and it is hoped they will improve use of TDM-guided anti-
TNF therapy among gastroenterologists in Australia and abroad. Evidence is most 
supportive for reactive TDM, however there are selected scenarios where proactive 
TDM for patients in remission may be beneficial, including treatment optimisation 
shortly following anti-TNF treatment induction and relapse risk stratification prior to an 
anti-TNF drug holiday. Limitations of the evidence and hence these consensus 
statements relate to endpoint and phenotype appropriate therapeutic ranges, scarce 
data on appropriate therapeutic ranges during anti-TNF drug induction, lack of 
longitudinal interventional studies on TDM of biologics in different disease phenotypes, 
and sparse TDM data on biologics other than infliximab and adalimumab. These 
consensus guidelines will need to be updated with emerging data that answers the 
above questions.  
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APPENDIX 
Table 1: NHMRC Evidence Hierarchy.[39]  
Designation of "level of evidence" according to type of research question 
Level Intervention Diagnostic 
accuracy 
Prognosis Aetiology Screening 
intervention 
I  
Systematic review of level II studies 
II RCT A study of test 
accuracy with: an 
independent, 
blinded 
comparison with 
a valid reference 
standard, among 
consecutive 
persons with a 
defined clinical 
presentation 
Prospective 
cohort study 
Prospective 
cohort study 
RCT 
III-1 Pseud-RCT (ie. 
alternate 
allocation or 
some other 
method) 
A study of test 
accuracy with: an 
independent, 
blinded 
comparison with 
a valid reference 
standard, among 
non-consecutive 
persons with a 
Case series 
where all or none 
of the people with 
the risk factor(s) 
experience the 
outcome 
 
Case series 
where all or none 
of the people with 
the risk factor(s) 
experience the 
outcome 
Pseudo-RCT (ie. 
alternate 
allocation or 
some other 
method 
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defined clinical 
presentation 
III-2 Comparative 
study with 
concurrent 
controls:  
 Non-
randomised, 
experimental 
trial 
 Cohort study  
 Case-control 
study  
 Interrupted time 
series with a 
control group  
A comparison 
with reference 
standard that 
does not meet 
the criteria 
required for Level 
II and III-1 
evidence 
Analysis of 
prognostic 
factors amongst 
persons in a 
single arm of a 
RCT 
Retrospective 
cohort study 
A comparative 
study with 
concurrent 
controls:  
 Non-
randomised, 
experimental 
trial  
 Cohort study  
 Case-control 
study 
III-3 Comparative 
study without 
concurrent 
controls:  
 Historical 
control study 
 Two or more 
single arm 
study 
 Interrupted time 
series without a 
parallel control 
group 
Diagnostic case-
control study 
 
Retrospective 
cohort study 
Case-control 
study 
A comparative 
study without 
concurrent 
controls:  
 Historical 
control study  
 Two or more 
single arm 
study 
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IV Case series with 
either post-test or 
pre-test/post-test 
outcomes 
Study of 
diagnostic yield 
(no reference 
standard) 
Case series, or 
cohort study of 
persons at 
different stages 
of disease 
Cross-sectional 
study or case 
series 
Case series 
RCT, randomised controlled trial 
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Table 2: NHMRC Body of evidence matrix.[39]  
Each of the five domains is ranked A-D and the grade of recommendation is taken as 
the average ranking.  
Component A B C D 
Excellent  Good Satisfactory Poor 
Evidence base 
(Level of evidence 
from NHMRC 
evidence 
hierarchy)  
one or more level 
I studies with a 
low risk of bias or 
several level II 
studies with a low 
risk of bias  
one or two level II 
studies with a low 
risk of bias or a 
SR/several level 
III studies with a 
low risk of bias  
one or two level 
III studies with a 
low risk of bias, 
or level I or II 
studies with a 
moderate risk of 
bias  
level IV studies, 
or level I to III 
studies/SRs with 
a high risk of bias  
Consistency (not 
applicable if only 
one study) 
all studies 
consistent 
most studies 
consistent and 
inconsistency 
may be explained 
some 
inconsistency 
reflecting genuine 
uncertainty 
around clinical 
question 
evidence is 
inconsistent 
Clinical impact Very large Substantial Moderate Slight or 
restricted 
Generalisability population/s 
studied in body of 
evidence are the 
same as the 
population/s 
studied in the 
body of evidence 
are similar to the 
population/s 
studied in body of 
evidence differ to 
target population 
for guideline but it 
is clinically 
population/s 
studied in body of 
evidence differ to 
target population 
and hard to judge 
whether it is 
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target population 
for the guideline  
target population 
for the guideline  
sensible to apply 
this evidence to 
target population  
sensible to 
generalise to 
target population  
Applicability  directly 
applicable to 
Australian 
healthcare 
context 
applicable to 
Australian 
healthcare 
context with few 
caveats 
probably 
applicable to 
Australian 
healthcare 
context with 
some caveats 
not applicable to 
Australian 
healthcare 
context 
SR, systematic review 
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Table 3: NHMRC grades of recommendation. [39] 
Grade of 
recommendation  
Description  
A  Body of evidence can be trusted to guide practice   
B Body of evidence can be trusted to guide practice in most 
situations    
C Body of evidence provides some support for 
recommendation(s) but care should be taken in its application   
D    Body of evidence is weak and recommendation must be 
applied with caution 
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Table 4: Studies defining a steady state therapeutic trough cut-off or range for 
infliximab in luminal IBD 
Study Study type Population Therapeutic 
cut-off or 
range (assay 
type) 
Endpoints 
Adedokun et 
al. 2014[118] 
Prospective 
cohort study 
(post-hoc 
analysis) 
N=85, UC in 
clinical remission, 
week 30 of IFX 
maintenance post 
initiation 
3.5 - 8.4μg/mL, 
therapeutic 
range (ELISA) 
Remission 
(Mayo score) at 
week 54 
 
Arias et al. 
2012[174] 
Retrospective 
cohort study  
N=135, UC, week 
14 post IFX 
induction 
>7.19μg/mL 
(ELISA)  
Sustained 
benefit (not 
defined) 
 
Ben-Bassat et 
al. 2013[127] 
Cross-
sectional study 
N=234, CD, 
maintenance IFX 
>2μg/mL 
(HMSA) 
Steroid-free 
clinical remission 
(HBI), 
endoscopic 
remission & CRP 
Bortlik et al. 
2013[128] 
Retrospective 
cohort study  
N=84, CD, week 
14 -22 following 
IFX initiation. 
Median follow up 
25 months (range 
14-37) 
>3μg/mL 
(ELISA) 
Treatment failure 
(loss of response 
or drug 
intolerance) on 
follow up 
(median 25 
116 
 
months, range 
14-37) 
Chaparro et 
al. 2016[147] 
Cross-
sectional study 
N=44, IBD, on 
IFX maintenance 
≥2.4μg/mL 
(ELISA) 
Mucosal healing  
Cornillie et al. 
2014[98] 
Retrospective 
cohort study 
(post hoc 
analysis of 
RCT)  
N=147, CD, week 
14 post IFX 
induction  
≥3.5ug/mL 
(ELISA) 
Clinical response 
at week 54 
(CDAI) 
Drobne et al. 
2011[129] 
Prospective 
cohort study 
N=117, CD, co 
treated with IFX & 
immunomodulator 
for 1 year, 
immunomodulator 
discontinued after 
1 year 
Detectable 
(ELISA, lower 
limit of 
detection not 
given) 
Maintained 
clinical response  
 
Drobne et al. 
2016[135] 
Prospective 
cross-sectional 
N=83, IBD, on 
IFX maintenance 
>6.4μg/mL 
(ELISA) 
Lower CRP and 
faecal 
calprotectin  
Echarri et al. 
2014[119] 
Prospective 
cross-sectional 
study 
N=15, CD, week 
14 post IFX 
induction  
>3μg/mL 
(ELISA) 
Clinical response 
or remission 
(HBI) 
Feagan et al. 
2012[80] 
Cross-
sectional study 
N=532, CD, not 
specified at what 
time point during 
≥3μg/mL 
(HMSA) 
Difference in 
CRP 
concentration 
117 
 
(post-hoc 
analysis)  
induction/ 
maintenance 
Huang et al. 
2015[130] 
Cross-
sectional study 
N=36, IBD, on 
maintenance IFX 
≥6.65μg/mL 
(ELISA)  
 
 
 
≥7.3μg/mL 
(ELISA) 
Clinical 
remission (HBI 
for CD, partial 
Mayo for UC) 
 
Faecal 
calprotectin 
<250μg/g 
Lamblin et al. 
2012[120] 
Cross-
sectional study 
N=44, CD, on 
maintenance IFX 
≥5.6μg/mL 
(assay not 
specified) 
CRP 
normalisation, at 
same time-point 
Levesque et 
al. 2014[121] 
Prospective 
cohort study 
N=327, CD on 
maintenance IFX 
(received at least 
5 infusions) 
>2.8-4.6μg/mL 
(HMSA)  
 
 
 
>2.7-2.8μg/mL 
(HMSA) 
Lack of CDAI 
increase of ≥70 
between two 
infusions  
 
Maintaining 
normal CRP  
Maser et al. 
2006[122] 
Prospective 
cohort study 
N=105, CD, week 
52 post IFX 
initiation 
>1.40μg/mL, 
detectable limit 
(ELISA) 
Clinical 
remission (HBI), 
CRP reduction, 
endoscopic 
improvement/ 
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remission (SES-
CD) 
Moore et al. 
2016[131] 
Meta-analysis IBD, 4 studies 
allowed remission 
rates to be 
pooled 
>2μg/mL Clinical 
remission, or 
endoscopic 
remission 
Papamichael 
et al. 
2016[116] 
Retrospective 
cohort study 
N=101, UC, week 
14 post IFX 
induction 
≥2.1μg/mL 
(ELISA) 
Mucosal healing 
at weeks 10-14 
(Mayo 
endoscopy score 
≤1) 
Seow et al. 
2010[123] 
Cross-
sectional study  
N=115, UC, 
maintenance IFX 
>1.40μg/mL, 
detectable limit 
(ELISA) 
Clinical 
remission (Mayo 
score) 
 
Steenholdt et 
al. 2011[134] 
Cross-
sectional study 
N=106, IBD, on 
IFX maintenance 
>0.5μg/mL for 
CD (RIA) 
 
>0.8μg/mL for 
UC (RIA) 
Maintaining 
clinical response 
 
Maintaining 
clinical response 
Ungar et al. 
2016[124] 
Cross-
sectional study 
N=78, IBD, on 
IFX maintenance 
6-10μg/mL, 
therapeutic 
range (ELISA) 
Mucosal healing 
(SES-CD or 
Mayo score) 
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Van Assche et 
al. 2008[136] 
Prospective 
cross-sectional 
N=, IBD, on IFX 
maintenance > 6 
months 
>2.24μg/mL 
(ELISA) 
 
 
>0.90 μg/mL 
(ELISA) 
Lower mean 
CRP between 
quartiles 3 and 
1/2  
 
Lower mean 
CDAI between 
quartiles 2 and 1  
Vande 
Casteele et al. 
2012[125] 
Prospective 
cohort study 
N=275, IBD, on 
maintenance IFX  
3-7μg/mL 
(ELISA) 
CRP reduction 
Vande 
Casteele et al. 
2013[175] 
Retrospective 
cohort study 
N =90, IBD, week 
14 post IFX 
initiation 
≥2.2μg/mL Remaining on 
IFX & lack of ATI  
 
Vande 
Casteele et al. 
2015[132] 
Cross-
sectional study 
N=483, CD, on 
maintenance IFX  
>2.79μg/mL 
(HMSA) 
CRP 
normalisation 
(<5mg/L) 
Warman et al. 
2015[133] 
Cross-
sectional study  
N=61, IBD, 
maintenance IFX  
≥2.18μg/mL 
(ELISA) for CD 
 
≥6.26μg/mL 
(ELISA) for UC 
Clinical 
remission (CDAI) 
 
Clinical 
remission 
(Truelove-Witts 
index) 
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Yanai et al. 
2015[82] 
Retrospective 
cohort study 
N=188, IBD 
patients with 
secondary loss of 
response to IFX 
>3.8μg/mL 
(ELISA) 
Failure to 
respond to dose 
escalation 
 
Hibi et al. 
2012[137] 
Cross-
sectional study 
N=57, CD, on IFX 
therapy at least 
14 weeks  
≥5μg/mL 
(ELISA) 
Clinical 
response/ 
remission (CDAI)  
ATI, Antibodies to infliximab; CRP, C reactive peptide; ELISA, enzyme-linked 
immunosorbent assay; CD, Crohn's disease; CDAI, Crohn’s disease activity index; HBI, 
Harvey Bradshaw Index; HMSA, homogeneous mobility shift assay; IBD, inflammatory 
bowel disease; IFX, infliximab; RCT, randomised controlled trial; RIA, radio-immunoassay; 
SES-CD, simplified endoscopic activity score for Crohn's disease; UC, ulcerative colitis;  
. 
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Table 5: Studies defining a steady state therapeutic trough cut-off or range for 
adalimumab in luminal IBD 
 
Study name Study type Population Therapeutic 
cut-off or 
range (assay 
type) 
Endpoints 
Chaparro et al. 
2016[147] 
Prospective  
cross-sectional 
N=26, IBD 
patients on ADA 
maintenance 
≥9.1μg/mL 
(ELISA) 
Mucosal healing  
Chiu et al. 
2013[138] 
Cross-sectional 
study (post hoc 
analysis) 
N=275, CD, 
levels at week 
4,24 and 56 
post ADA 
initiation 
Cut-off not 
identified as 
considerable 
overlap (ELISA) 
Clinical 
remission or 
response (CDAI) 
Echarri et al. 
2014[119] 
Prospective 
cohort study 
N=17, CD, ADA 
trough at week 
14 post initiation 
>4.5 /mL 
(ELISA) 
Good response 
(not defined) and 
remission (HBI 
<5) 
Imaeda et al. 
2014[139] 
Cross-sectional 
study 
N=40, CD, on 
ADA 
maintenance 
≥5.9μg/mL 
(ELISA) 
Undetectable 
CRP 
(≤0.3mg/dL) 
Mazor et al. 
2014[140] 
Cross-sectional 
study 
N=71, CD, on 
ADA 
maintenance 
>5.85μg/mL 
(ELISA, drug-
tolerant) 
Remission 
(physician global 
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assessment) and 
CRP normal 
Roblin et al. 
2014[142] 
Cross-sectional 
study 
N=40, IBD, 
maintenance 
therapy 
≥4.9μg/mL 
(ELISA) 
Mucosal healing 
(endoscopic 
Mayo score for 
UC, no 
ulceration for 
CD) 
Roblin et al. 
2014[83] 
Prospective 
cohort study 
N=82, IBD (55% 
CD, 45% UC), 
secondary loss 
of response to 
ADA  
>4.9μg/mL 
(ELISA) 
Response to 
dose escalation 
Sharma et al. 
2015[143] 
Cross-sectional 
study 
N=192, 
Paediatric CD, 
at weeks 26 and 
52 following 
ADA initiation 
≥3.6μg/mL 
(ELISA) 
 
 
 
≥5.3μg/mL 
(ELISA) 
 
Clinical 
remission at 
week 26 (PCDAI 
≤10) 
 
Clinical 
remission at 
week 52 (PCDAI 
≤10) 
Ungar et al. 
2016[124] 
Retrospective 
cross-sectional 
study 
N=67, IBD, ADA 
maintenance 
treatment 
7 – 12μg/mL 
range (ELISA, 
drug tolerant) 
Mucosal healing 
(SES-CD or 
Mayo score) 
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Velayos et al. 
2013[144] 
Cross-sectional 
study 
N=54, IBD (52 
CD, 2 UC), ADA 
maintenance 
treatment 
>5μg/mL 
(HMSA) 
CRP 
normalisation 
and remission/ 
response (self 
reported 
questionnaire) 
Ward et al. 
2013[149]  
Cross-sectional 
study 
N=31, IBD (27 
CD, 3 IBDU, 1 
UC), ADA 
maintenance 
treatment 
≥4.9μg/mL 
(ELISA) 
Clinical 
remission  
Yanai et al. 
2015[82] 
Retrospective 
cohort study 
N=142, IBD 
patients with 
secondary loss 
of response to 
ADA 
>4.5μg/mL 
(ELISA) 
Failure to 
respond to dose 
escalation  
 
Yarur et al. 
2013[145] 
Cross-sectional 
study 
N=66, IBD (59 
CD, 7 UC), 
maintenance 
treatment 
>5μg/mL 
(HMSA) 
CRP 
normalisation 
(level not 
specified) 
Yarur et al. 
2016[146] 
Cross-sectional 
study 
N=66, IBD on 
maintenance 
ADA 
≥7.5μg/mL 
(HMSA)  
 
 
 
 
Endoscopic 
remission (no 
inflammatory 
findings on 
endoscopy) 
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≥7.8μg/mL  
(HMSA) 
Histological 
remission (no 
inflammation on 
biopsies) 
ADA, adalimumab; ATA, antibodies to adalimumab; CD, Crohn's disease; CDAI, Crohn’s 
disease activity index; CRP, C reactive peptide; ELISA, enzyme-linked immunosorbent 
assay; HBI, Harvey Bradshaw Index; HMSA, homogeneous mobility shift assay; IBD, 
inflammatory bowel disease; IBDU, IBD-unclassified; PCDAI, paediatric Crohn’s disease 
activity index; SES-CD, simplified endoscopic activity score for Crohn's disease; UC, 
ulcerative colitis 
 
  
125 
 
Table 6: Nominated panel members 
Name of nominee Initials Occupation Place of 
practice 
Accepted/ 
declined 
nomination 
Prof Rupert Leong RL Gastroenterologist Australia, NSW Accepted 
A/ Prof Susan 
Connor 
SC Gastroenterologist Australia, NSW Accepted 
Dr Simon Ghaly SG Gastroenterologist Australia, NSW Accepted 
Prof Michael 
Grimm 
MG Gastroenterologist Australia, NSW Accepted 
A/Prof Daniel 
Lemberg 
DL Paediatric 
gastroenterologist 
Australia, NSW Accepted 
Dr Viraj 
Kariyawasam 
VK Gastroenterologist Australia, NSW Accepted 
Dr Crispin Corte CC Gastroenterologist Australia, NSW Accepted 
Dr Nikola Mitrev NM IBD research 
registrar 
Australia, NSW Accepted 
Dr Greg Moore GM Gastroenterologist Australia, VIC Accepted 
Dr Mark Ward MW Gastroenterologist Australia, VIC Accepted 
Prof Peter Gibson PG Gastroenterologist Australia, VIC Declined 
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Dr Miles Sparrow MS Gastroenterologist Australia, VIC Accepted 
Dr Daniel van 
Langenberg 
DVL Gastroenterologist Australia, VIC Accepted 
A/Prof Peter 
Lewindon 
PL Paediatric 
gastroenterologist 
Australia, QLD Accepted 
Dr Jakob Begun JB Gastroenterologist Australia, QLD Accepted 
A/Prof Graham 
Radford-Smith 
GRS Gastroenterologist Australia, QLD Accepted 
Prof Jane M. 
Andrews 
JMA Gastroenterologist  Australia, SA Accepted 
Dr Robert Bryant RB Gastroenterologist Australia, SA Accepted 
Dr Reme 
Mountifield 
RM Gastroenterologist Australia, SA Accepted 
Dr Kannan 
Venugopal 
KV Gastroenterologist Australia, WA Accepted 
A/Prof Cynthia 
Seow 
CS Gastroenterologist Canada Accepted 
Prof Murray 
Barclay 
MB Gastroenterologist New Zealand Accepted 
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Dr Niels Vande 
Casteele 
NVC Clinical 
pharmacologist 
United States 
of America, 
California 
Accepted 
Prof Jennifer 
Martin 
JM Clinical 
pharmacologist 
Australia, NSW Accepted 
Peter Slobodian PS Clinical pharmacist Australia, NSW Accepted 
Dr Catherine 
Toong 
CT Immunologist Australia, NSW Accepted 
 
  
128 
 
Table 7: Papers and abstracts sent to panel members following the second 
round of voting 
Reference Predetermined clinical question 
addressed by article (Table 2, 
Methods, for questions) 
Adedokun et al. 2014[118] 1 
Adendokun et al. 2016[214] 8 
Afif et al. 2010[200] 4,6,7 
Allgretti et al. 2016[218] 5,6,7 
Amin et al. 2016[99] 7 
Amiot et al. 2016[101] 5, 6, 7 
Arias et al. 2016[174] 1 
Armuzzi et al. 2014[104] 6, 7 
Baert et al. 2003[14] 2 
Baert et al. 2014[197] 2 
Baert et al. 2015[97] 1 
Battat et al. 2016[215] 8 
Ben-Bassat et al. 2013[127] 1,2 
Ben-Horin et al. 2013[203] 4, 6, 7 
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Ben-Horin et al. 2015[219] 5,6,7 
Bortlik et al. 2013[128] 1 
Brandse et al. 2014[49]  1, 2, 7 
Brandse et al. 2016[100] 2,5,6,7 
Brandseet al. 2015[163] 7 
Bressler et al. 2015[244] 4 
Chaparro et al. 2016[147] 1 
Chiu et al. 2013[138] 1 
Connor 2016[228] 2, 6, 7 
Cornillie et al. 2014[98] 1, 2, 6, 7 
Dalal et al. 2015[227] 4 
Davidov et al. 2016[185] 1 
D'Haens et al. 2016[103] 5,6,7 
Ding et al. 2015[41] 2, 6, 7 
Drobne et al. 2011[129] 1 
Drobne et al. 2016[135] 1 
Echarri et al. 2014[119] 1 
Eser et al. 2013[152] 1, 2, 5, 6, 7 
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Fegan et al. 2012[80] 1 
Feurestein et al. 2015 [196] 2 
Flamant et al. 2015[220] 5, 6, 7 
Gibson et al. 2015[106] 7 
Gils et al. 2014[78] 3 
Gils et al. 2016[86] 3 
Gisbert et al 2016[222] 5,6,7 
Glovics et al. 2016[171] 2,3, 6 
Guidi et al. 2016[250] 4,6,7 
Guiotto et al. 2016[73] 2, 3 
Halpin et al. 2012[233] 6 
Hibi et al 2012[137] 1 
Huang et al. 2015[130] 1 
Imaeda et al. 2014[139] 1 
Karmiris et al. 2009[208] 2 
Katz et al. 2012[249] 4,6,7 
Khanna et al. 2013[229] 2, 6, 7 
Klotz et al. 2007[155] 6 
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Kobayashi et al. 2016[254] 7 
Lallemand et al. 2011[69] 3 
Lamblin et al. 2012[120] 1 
Leclerc et al. 2014[207] 2 
Lee et al. 2016[247] 4 
Lee et al. 2016[77] 3 
Levesque et al. 2014[121] 1 
Lin et al. 2014[202] 2, 6, 7 
Louis et al. 2012[221] 5,6,7 
Malickova et al. 2016[74] 3 
Maser et al. 2006[122] 1 
Mazor et al. 2014[140] 1 
Melmed et al. 2016[31] 2, 6, 7 
Menting et al. 2015[216] 8 
Minar et al. 2016[209] 2 
Moore et al. 2016[131] 1 
Mosli et al. 2015[240] 4 
Mostafa et al. 2013[141] 1 
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Nanda et al. 2013[194] 2 
Nguyen et al. 2008[245] 4 
Nguyen et al. 2015[93] 2,6,7 
Ordas et al. 2012[153] 6 
Ordas et al. 2012[255] 2, 6, 7 
Osterman et al. 2016[211] 8 
O'Toole et al. 2015[42] 2, 6, 7 
Papamichael et al. 2015[165] 1, 2, 6, 7 
Papamichael et al. 2015[182] 5,6,7 
Papamichael et al. 2016[116] 1 
Pariente et al. 2012[201] 1, 2 
Paul et al. 2014[195] 2 
Quingley et al. 2015[238] 4 
Roblin et al. 2014[142] 1 
Roblin et al. 2014[83] 1, 2, 4, 6, 7 
Rosario et al. 2015[212] 8 
Rosen et al. 2015[256] 2, 6, 7 
Schmitz et al. 2015[75] 3 
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Scott et al. 2014[65] 3 
Seow et al. 2010[123] 1 
Sharma et al. 2015[143] 1 
Singh et al. 2014[96] 5,6,7 
Sorrentino et al. 2016[248] 2, 6, 7 
Steenhold et al. 2012[206] 2 
Steenholdt et al. 2011[134] 1,2 
Steenholdt et al. 2012[20] 2, 5,6,7 
Steenholdt et al. 2013[70] 3 
Steenholdt et al. 2014[71] 3 
Steenholdt et al. 2014[87] 4, 6, 7 
Steenholdt et al. 2015[21] 2 
Steenholdt et al. 2015[198] 2 
Steenholdt et al. 2015[81] 3 
Steenholdt et al. 2015[87] 4, 6, 7 
Steenholdt et al. 2015[91] 4, 6, 7 
Steenholdt et al. 2016[19] 2, 6, 7 
Stein et al. 2016[94] 4, 5, 7 
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Strik et al. 2016[43] 2, 6, 7 
Svenson et al. 2007[79] 3 
Swoger et al. 2014[199] 1, 6 
Ternant et al. 2008[154] 4, 5, 6, 7 
Ungar et al. 2014[188] 2, 5, 6, 7 
Ungar et al. 2016[124] 1 
Ungar et al. 2016[204] 1 
Van Assche et al. 2008[136] 1 
van Bezooijen et al. 2016[72] 3 
Van Stappen et al. 2016[67] 3 
Van Stappen et al. 2016[107] 7 
Vande Casteele et al. 2012[125] 1 
Vande Casteele et al. 2013[175] 1, 2,5 ,6,7 
Vande Casteele et al. 2014[44] 2, 6, 7 
Vande Casteele et al. 2015[132] 1, 2 
Vande Casteele et al. 2015[46] 2,3,5,6,7 
Vande Casteele et al. 2015[102] 4, 6, 5, 7 
Vaughn et al. 2014[105] 5, 6, 7 
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Vaughn et al. 2015[63] 3 
Velayos et al. 2013[144] 1 
Velayos et al. 2013[95] 4,6,7 
Viola et al. 2009[210] 2 
Wang et al. 2012[64] 3 
Ward et al. 2013[149] 1 
Ward et al. 2016[150] 1, 7 
Warman et al. 2015[133] 1 
Weisshof et al. 2016[257] 2 
Williet et al. 2016[213] 8 
Yamamotto et al. 2016[243] 4 
Yanai et al. 2015[82] 1,2,4,5,6,7 
Yarur 2015[45] 2, 6, 7 
Yarur et al. 2013[145] 1 
Yarur et al. 2016[126] 1 
Yarur et al. 2016[146] 1 
Yarur et al. 2016[167] 1, 4 
Zittan et al. 2016[172] 1 
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Table 8: First draft of the consensus statements on TDM-guided anti-TNF 
therapy in IBD 
1. Target drug trough levels 
1a. In patients with luminal disease we generally recommend a steady state trough 
infliximab level between 3.8 and 8.4 µg/mL. 
1b. In patients with luminal disease we generally recommend a steady state 
adalimumab trough level between 4.9 and 8.7 µg/mL. 
1c. In certain situations higher trough levels than the above ranges may be 
appropriate. 
2. Interpreting anti-drug antibodies 
2a. When interpreting anti-drug antibodies, quantifying titres is clinically more 
useful than positive/ negative status.  
2b. When interpreting anti-drug antibodies, repeat testing is useful to determine if 
antibodies are transient or persistent before acting on a result, particularly for 
patients that meet criteria for clinical remission.  
3. Scenarios for therapeutic drug monitoring 
3a. Patients should have therapeutic drug monitoring performed when in steady 
state following induction therapy whether or not they achieve clinical remission.  
3b. Patients with secondary loss of response at any time should have therapeutic 
drug monitoring performed in order to guide clinical decision making. 
3c. Patients maintained in clinical remission are suggested to have periodic testing 
performed every one to two years. 
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3d. Therapeutic drug monitoring should not be performed in scenarios where 
results will not influence clinical decisions. 
4. Interpreting drug levels in patients with confirmed active inflammatory 
disease  
4a. Patients with confirmed active inflammatory disease and therapeutic drug 
trough levels (suggests pharmacodynamic failure) should be switched out-of-class. 
4b. Patients with confirmed active inflammatory disease and sub-therapeutic drug 
trough levels & no detectable anti-drug antibodies (suggests non-immune 
mediated pharmacokinetic failure) should have compliance checked first, followed 
by dose escalation. 
4c. Patients with confirmed active inflammatory disease and undetectable drug 
trough levels & low titres of anti-drug antibodies (suggests immune mediated 
pharmacokinetic failure) should have an immunomodulatory added/ optimised & 
anti-TNF dose escalation. 
4d. Patients with confirmed active inflammatory disease and & undetectable drug 
trough levels & high titres of anti-drug antibodies (suggests immune mediated 
pharmacokinetic failure) should be switched within class. 
5. Interpreting drug levels among patients in clinical remission: 
5a. Patients in clinical remission and therapeutic drug trough levels should be 
continued on the same dose. 
5b. Patients in clinical remission and with supra-therapeutic drug trough levels 
should be considered for dose reduction. 
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5c. Patients in clinical remission and with sub-therapeutic drug trough levels 
should be individually assessed for suitability for a drug holiday. 
5d. Patients in clinical remission who are deemed not suitable for a drug holiday, 
and with sub-therapeutic drug trough levels & undetectable anti-drug antibodies 
should have dose escalation. 
5e. Patients in clinical remission who are deemed not suitable for a drug holiday, 
and with sub-therapeutic drug trough levels & low titres of anti-drug antibodies 
should have an immunomodulatory added/ optimised & dose escalation. 
5f. Patients in clinical remission who are deemed not suitable for a drug holiday, 
and with undetectable drug trough levels & high titres of anti-drug antibodies, 
should be switched within class. 
6. General steps to take for patients with symptoms of clinically active 
disease on anti-TNF therapy along with therapeutic drug monitoring: 
6a. Patients with clinically active disease on anti-TNF therapy should have active 
inflammatory disease confirmed via objective measures (endoscopy, radiology 
and/or biochemistry).  
6b. Patients with clinically active disease on anti-TNF therapy should have 
investigations to exclude other causes of symptoms along with therapeutic drug 
monitoring.  
6c. Patients with confirmed active inflammatory disease on anti-TNF therapy 
should have other IBD treatments optimised along with performing therapeutic 
drug monitoring.  
7. Standards for therapeutic drug monitoring 
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7. We recommend the use of a drug-tolerant assay over a drug sensitive assay for 
measurement of anti-drug antibodies. 
8. TDM for non-anti-TNF biologics 
8. Due to lack of evidence on appropriate troughs associated with specific 
endpoints for non-anti-TNF biologic agents currently used in IBD, we cannot 
recommend routine use of therapeutic drug monitoring to guide clinical decision 
making. 
9. Future directions 
9. Data on therapeutic drug monitoring should be available at time of registration 
for all future biologics. 
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Table 9: Final consensus on TDM-guided anti-TNF therapy in IBD following 
three iterations of a modified Delphi method  
Statements in grey did not reach consensus. 
1. Scenarios when TDM of anti-TNF agents should be performed 
1a. In patients in clinical remission following anti-TNF therapy induction, TDM should 
be considered to guide management.  
1b. Therapeutic drug monitoring can inform clinical decision making in patients with 
primary non-response 
1c. Therapeutic drug monitoring should be performed in patients with secondary loss 
of response to guide clinical decision making 
1d. TDM should be considered periodically in patients in clinical remission if the 
results are likely to impact management. 
1e. Patients maintained in clinical remission in whom a drug holiday is contemplated, 
are suggested to have therapeutic drug monitoring along with other investigations to 
help guide this decision 
2. General approach to patients with symptoms of active disease on anti-TNF 
therapy 
2. Patients with symptoms of active disease on anti-TNF therapy should have active 
inflammatory disease confirmed via objective measures (endoscopy, imaging, 
serum/ faecal biomarkers) and investigations to exclude alternative/ concomitant 
causes of symptoms, prior to change in therapy. 
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3. Interpreting TDM results in patients with confirmed active inflammatory 
disease on anti-TNF therapy 
3a. Patients with confirmed active inflammatory disease and therapeutic drug trough 
levels (suggests pharmacodynamic failure) should be switched out-of-class. 
3b. Patients with confirmed active inflammatory disease, sub-therapeutic drug trough 
levels and no detectable anti-drug antibodies (suggests non-immune mediated 
pharmacokinetic failure) should have adherence checked first followed by dose 
escalation of the anti-TNF agent. Optimization/ introduction of an immunomodulator 
should be considered. 
3c. Patients with confirmed active inflammatory disease, sub-therapeutic drug trough 
levels and low titres of anti-drug antibodies (suggests immune mediated 
pharmacokinetic failure) should have an immunomodulatory added/ optimised and/or 
anti-TNF dose escalation. 
3d. Patients with confirmed active inflammatory disease, undetectable drug trough 
levels and high titres of anti-drug antibodies (suggests immune mediated 
pharmacokinetic failure) should be switched within class for secondary loss of 
response, or alternatively switched within class or switched out-of-class for primary 
non-response. 
4. Interpreting TDM results among patients in clinical remission on anti-TNF 
therapy 
4a. Patients in clinical remission and therapeutic drug trough levels should be 
continued on the same dose. 
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4b. Patients in clinical remission and with supra-therapeutic drug trough levels 
should be considered for dose reduction. 
4c. Patients in clinical remission and with sub-therapeutic drug trough levels should 
be individually assessed for suitability for a drug holiday (consensus not reached). 
4d. Patients in clinical remission who have high risk features, sub-therapeutic drug 
trough levels and undetectable anti-drug antibodies should have optimization or 
addition of an immunomodulator and/ or dose escalation 
4e. Patients in clinical remission who have high risk features, with sub-therapeutic 
drug trough levels and low titres of anti-drug antibodies should have an 
immunomodulatory added/ optimised and/ or dose escalation. 
4f. Patients in clinical remission who have high risk features, with undetectable drug 
trough levels and persistently high titres of anti-drug antibodies, should be 
considered for switching within or out-of-class. 
5. Target drug trough levels 
5a. In patients with luminal disease we generally recommend a steady state trough 
infliximab level between 3 and 8μg/mL  
5b. In patients with luminal disease we generally recommend a steady state 
adalimumab trough level between 5 and 12 μg/mL. 
5c. In certain situations higher or lower trough levels than the above ranges may be 
appropriate. 
6. Anti-drug antibodies 
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6a. When interpreting anti-drug antibodies, quantifying titres is clinically more useful 
than positive/ negative status.  
6b. When interpreting anti-drug antibodies, repeat testing is useful to determine if 
antibodies are transient or persistent before acting on a result, particularly for 
patients that meet criteria for clinical remission. 
6c. There is insufficient evidence to recommend a drug-tolerant assay for anti-drug 
antibody detection 
7. TDM for non-anti-TNF biologics and future therapies 
7a. There is emerging evidence that trough levels of non-anti-TNF biological agents 
may be relevant to clinical endpoints. However, more longitudinal data are required 
before routine use of therapeutic drug monitoring to guide clinical decision making on 
the use of non-anti-TNF biological agents. 
7b. Data on therapeutic drug monitoring should be available at time of registration for 
all future therapies (consensus not reached). 
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